

Guide to HEDIS® Measures MY 2021

Prepared by:
Quality Performance Management
HEDIS® Operations

Version 14_03/2021

LA1494 02/21



L.A. Care
HEALTH PLAN®

For All of L.A.

Table of Contents



For All of L.A.

Welcome to Guide to HEDIS® Measures.....	1
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (AAB).....	2
Adults' Access to Preventative/Ambulatory Health Services (AAP)	4
Follow-Up Care for Children Prescribed ADHD Medication (ADD).....	6
Antidepressant Medication Management (AMM).....	9
Asthma Medication Ratio (AMR).....	12
Breast Cancer Screening (BCS)	15
Controlling High Blood Pressure (CBP)	18
Cervical Cancer Screening (CCS)	21
Comprehensive Diabetes Care (CDC)	24
Chlamydia Screening in Women (CHL)	29
Childhood Immunization Status (CIS)	31
Care for Older Adults (COA).....	35
Colorectal Cancer Screening (COL).....	40
Cardiac Rehabilitation (CRE)	43
Appropriate Testing for Children with Pharyngitis (CWP)	45
Use of High-Risk Medications in the elderly (DAE).....	48
Potentially Harmful Drug-Disease Interactions in the Elderly (DDE)	52
Depression Screening and Follow-up for Adolescents and Adults (DSF-E*)	58
Follow-Up After Hospitalization for Mental Illness (FUH).....	61
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET).....	64
Immunizations for Adolescents (IMA)	67
Kidney Health Evaluation for Patients With Diabetes (KED)	70
Use of Imaging Studies for Low Back Pain (LBP).....	73
Osteoporosis Management in Women Who Had a Fracture (OMW)	75
Osteoporosis Screening in Older Women (OSW).....	79
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	81
Pharmacotherapy Management of COPD Exacerbation (PCE).....	83
Plan All-Cause Readmissions (PCR).....	86
Proportion of days Covered (PDC).....	88
Prenatal and Postpartum Care (PPC)	91
Statin Therapy for Patients with Cardiovascular Disease (SPC).....	96
Statin Therapy for Patients with Diabetes (SPD).....	100
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	104
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	106
Transitions of Care (TRC).....	110
Appropriate Treatment for Children with Upper Respiratory Infection (URI).....	113
Well-Child Visits in the First 30 Months of Life (W30).....	115
Weight Assessment and Counseling for Nutrition & Physical Activity for Children/Adolescents (WCC)	118
Child and Adolescent Well-Care Visits (WCV)	120

Welcome to Guide to HEDIS® Measures MY 2021



For All of L.A.

L.A. Care Health Plan (L.A. Care) is an National Committee for Quality Assurance (NCQA) accredited health plan. HEDIS® is the gold standard for measuring quality health care performance, and is part of the NCQA accreditation process. Guide to HEDIS® Measures is a reference guide designed to help your practice provide the best quality care, in alignment with the HEDIS® standards. This document is merely a tool and provides a general summary on some limited HEDIS® Program requirements. This document should not be used as legal advice or expert advice or comprehensive summary of the HEDIS® Program. Please refer to [ncqa.org](https://www.ncqa.org) for HEDIS® Program measures and guidelines as well as relevant statutes.

The information provided in this document is for 2021 HEDIS® measurement period and is current at the time this document was created. NCQA HEDIS® Program requirements, applicable laws, and L.A. Care's policy change from time to time, and information and documents requested from you may also change to comply with these requirements

L.A. Care is not affiliated with NCQA or its HEDIS® Program and does not receive any financial remuneration from it.

Guide to HEDIS® Measures highlights 39 priority HEDIS® measures that can potentially have significant impact on Auto-assignment and Minimum Performance Level (MPL), NCQA Accreditation, and Cal Medi-Connect (CMC) Quality Performance Withhold. Additionally, if you participate in and qualify for Physician P4P, the information contained in this reference guide may help you maximize the incentives you receive as part of L.A. Care's Physician Pay-for-Performance Program for Medi-Cal and L.A. Care Covered members.

L.A. Care Health Plan collects HEDIS® data throughout the measurement year and reports annually from January to May for the prior year. For example, 2021 claims, encounters, and other HEDIS® data are submitted throughout 2021. In January to May of 2022, data for 2021 continues to be submitted along with Medical Record review for Hybrid measures and final HEDIS® 2021 rates and results are reported.

For HEDIS® related inquiries, please contact HEDIS_Ops@lacare.org. *Note: All emails containing member PHI MUST be securely encrypted.*

Pay-for-Performance: Look for measures with Pay-for-Performance that are included in L.A. Care's Pay-for-Performance programs for Measurement Year 2021.

For more details contact incentive_ops@lacare.org. *Note: All emails containing member PHI MUST be securely encrypted.*

Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (AAB)

State Medicaid MPL (must achieve 50th percentile or greater)
Pay-for-Performance (P4P)
NCQA Accreditation Medicaid

Q: Which members are included in the sample?

A: Members ages 3 months and older with a diagnosis of acute bronchitis/bronchiolitis that were not dispensed an antibiotic treatment.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence from claim/encounter data with a date of service from any outpatient, telephonic, e- visit or virtual check-in, an observation or ED visit with an acute bronchitis diagnosis and no new or refill prescription for an antibiotic medication in 2021.

AAB Antibiotic Medications

Description	Prescription
Aminoglycosides	• Amikacin • Gentamicin • Tobramycin
Aminopenicillins	• Amoxicillin • Ampicillin
Beta-lactamase inhibitors	• Amoxicillin-clavulanate • Ampicillin-sulbactam • Piperacillin-tazobactam • Ticarcillin-clavulanate
First-generation cephalosporins	• Cefadroxil • Cefazolin • Cephalexin
Fourth-generation cephalosporins	• Cefepime
Ketolides	• Telithromycin
Lincomycin derivatives	• Clindamycin • Lincomycin
Macrolides	• Azithromycin • Clarithromycin • Erythromycin • Erythromycin ethylsuccinate • Erythromycin lactobionate • Erythromycin stearate
Miscellaneous antibiotics	• Aztreonam • Chloramphenicol • Dalacinin-guanipristin • Daptomycin • Erythromycin-sulfisoxazole • Linezolid • Metronidazole • Vancomycin
Natural penicillins	• Penicillin G benzathine-procaine • Penicillin G potassium • Penicillin G sodium • Penicillin V potassium • Penicillin G benzathine
Penicillins resistant penicillins	• Dicloxacillin • Nafcillin • Oxacillin
Quinolones	• Ciprofloxacin • Gemifloxacin • Levofloxacin • Moxifloxacin • Norfloxacin • Ofloxacin
Rifamycin derivatives	• Rifampin
Second-generation cephalosporins	• Cefaclor • Cefotetan • Cefoxitin • Cefprozil • Cefuroxime
Sulfonamides	• Sulfadiazine • Sulfamethoxazole-trimethoprim
Tetracyclines	• Doxycycline • Minocycline • Tetracycline
Third-generation cephalosporins	• Cefdinir • Cefditoren • Cefixime • Ceftriaxone • Cefuroxime • Cefixime • Ceftriaxone
Urinary anti-infectives	• Fosfomycin • Nitrofurantoin • Nitrofurantoin macrocrystals • Trimethoprim

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Use of complete and accurate Value Set Codes.
- ☒ Timely submission of claim/encounter data

Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (AAB)

State Medicaid MPL (must achieve 50th percentile or greater)
Pay-for-Performance (P4P) NCQA Accreditation
Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

Acute Bronchitis	J20.0-J20.9
------------------	-------------

CPT codes

Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99429, 99455, 99456
------------	--

CPT Telephonic and Telehealth codes

99443, 98966-98968, 99444, 99212-99215, 99201-99205

CPT Modifier codes for telehealth

95, GT, 02

HCPCS codes

Outpatient	G0402, G0438, G0439, G0463, T1015
------------	-----------------------------------

Exclusion(s)

Comorbid Conditions, Competing Diagnosis, COPD, Cystic Fibrosis, Disorders of Immune System, Emphysema, HIV, HIV Type 2, Malignant Neoplasms, Other Malignant Neoplasms of Skin, and Pharyngitis.

Note: Do not include visits that result in inpatient stay.

Adult's Access to Preventative/ Ambulatory Health Services (AAP)

Q: Which members are included in the sample?

A: Members 20 years and older who had an ambulatory or preventative care visit.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of medical record is acceptable?

A: Evidence from a claim/encounter with a date of service.

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Use every visit (including sick visits) to provide a well-child visit
- ☒ Use standardized templates for WCV in Electronic Health Records (EHR)
- ☒ Use of complete and accurate Value Set Codes.
- ☒ Timely submission of claims and encounter data

Adult's Access to Preventative/ Ambulatory Health Services (AAP)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

N/A

CPT codes

98966-98968, 99212-99215, 99441-99444

HCPCS codes

G0402, G0438-39, G0463, G2010, G2012, G2061-63, S0620-21, T1015

Exclusion(s)

None

Follow-Up Care for Children Prescribed ADHD Medication (ADD)

NCQA Accreditation Medicaid

Q: Which members are included in the sample?

A: Children 6-12 years newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication that had at least three follow-up care visits within a 10-month period;

- ☒ *One follow-up visit within 30 days of when the first ADHD medication was dispensed*
- ☒ *One follow-up visit with evidence that the member remained on ADHD medication for at least 210 days (7 months)*
- ☒ *Member had 2 follow-up visits within 270 days (9 months) after the Initiation Phase ended*

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Follow-Up Care for Children Prescribed ADHD Medication (ADD)

NCQA Accreditation Medicaid

Q: What type of document is acceptable?

A: Evidence from claim/encounter data:

1. Children in the specified age range who were dispensed an ADHD medication:

ADHD Medications		
Description	Prescription	
CNS stimulants	• Dexmethylphenidate	• Methylphenidate
	• Dextroamphetamine	• Methamphetamine
	• Lisdexamfetamine	
Alpha-2 receptor agonists	• Clonidine	• Guanfacine
Miscellaneous ADHD medications	• Atomoxetine	

2. Member follow-up visit with a practitioner with prescribing authority, within 30 days of ADHD medication dispensing:
 - Of these members, in the following 9 months, who received at least 2 additional follow-up visits with any practitioner

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data for any of the following: outpatient visit ,observation visit, Health and Behavior assessment or intervention visit, intensive outpatient encounter or partial hospitalization visit,Community Mental Health Center visit,telephone visit, E- Visit or Virtual Check- In.
- ☑ Schedule 30-day follow-up for all children who are dispensed ADHD medication to assess how medication is working

Follow-Up Care for Children Prescribed ADHD Medication (ADD)

NCQA Accreditation Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

Attention-Deficit Hyperactivity Disorder: F90.0-F90.2, F90.8-F90.9

CPT codes

ADD Stand Alone Visits	96150-96154, 98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99401-99404, 99411, 99412, 99510
ADD Visits Group 1	90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876
ADD Visits Group 2	99221-99223, 99231-99233, 99238, 99239, 99251-99255
Outpatient	99391-99394

CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

CPT Modifier codes for telehealth

95, GT, 02

HCPCS codes

ADD Stand Alone Visits	G0155, G0176, G0177, G0409- G0411, G0463, H0002, H0004, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, M0064, S0201, S9480, S9484, S9485, T1015
------------------------	---

Exclusion(s)

Acute Inpatient, Mental Disorder, Behavioral Disorder, Neurodevelopmental Disorder, Narcolepsy

Antidepressant Medication Management (AMM)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Q: Which members are included in the sample?

A: Adults 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression and who remained on an antidepressant medication treatment for at least 84 days (12 weeks) or for at least 180 days (6 months).

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Antidepressant Medication Management (AMM)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Q: What type of document is acceptable?

A: Evidence from claim/encounter data:

1. Diagnosis of major depression and date of the earliest dispensing event for an antidepressant medication:

Antidepressant Medications

Description	Prescription		
Miscellaneous antidepressants	• Bupropion	• Vilazodone	• Vortioxetine
Monoamine oxidase inhibitors	• Isocarboxazid	• Selegiline	
	• Phenelzine	• Tranylcypromine	
Phenylpiperazine antidepressants	• Nefazodone	• Trazodone	
Psychotherapeutic combinations	• Amitriptyline-chlordiazepoxide		• Fluoxetine-olanzapine
	• Amitriptyline-perphenazine		
SNRI antidepressants	• Desvenlafaxine	• Levomilnacipran	
	• Duloxetine	• Venlafaxine	
SSRI antidepressants	• Citalopram	• Fluoxetine	• Paroxetine
	• Escitalopram	• Fluvoxamine	• Sertraline
Tetracyclic antidepressants	• Maprotiline	• Mirtazapine	
Tricyclic antidepressants	• Amitriptyline	• Desipramine	• Nortriptyline
	• Amoxapine	• Doxepin (>6 mg)	• Protriptyline
	• Clomipramine	• Imipramine	• Trimipramine

2. Calendar days covered with prescriptions within the specified 180-day (6-month) measurement interval based on pharmacy claims.

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Submission of services rendered during a telephone visit, e-visit, or virtual check-in meet criteria.
- ☑ Follow Practice Guidelines for the Treatment of Patients with Major Depressive Disorders
- ☑ Treat members with diagnosis of major depression for at least six months
- ☑ Utilize the PHQ-9 assessment tool in management of depression
- ☑ Educate members that it might take up to 4 weeks for therapeutic effect and of possible medication side effects

Antidepressant Medication Management (AMM)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes	
Major Depression	F32.0-F32.4, F32.9, F33.0-F33.3, F33.41, F33.9

CPT codes	
AMM Stand Alone Visits	98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99510
AMM Visits	90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90867-90870, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251-99255
ED	99281-99285

CPT Telephonic and Telehealth codes	
99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205.	

CPT Modifier codes for telehealth	
95, GT, 02	

HCPCS codes	
AMM Stand Alone Visits	G0155, G0176, G0177, G0409-G0411, G0463, H0002, H0004, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, M0064, S0201, S9480, S9484, S9485, T1015

Exclusion(s)	
No diagnosis of Major Depression	

Asthma Medication Ratio (AMR)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

Q: Which members are included in the sample?

A: Members 5-64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during 2021.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: None. This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Use of complete and accurate Value Set Codes.
- ☒ Timely submission of claim/encounter data

Asthma Medication Ratio (AMR)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

Q: What type of document is acceptable?

A: Evidence from claim/encounter data with documentation of all asthma medications for members identified as having persistent asthma during 2021.

Asthma Controller Medication Prescription Medication List

Description	Prescription	Medication Lists	Route
Antiasthmatic combinations	• Dyphylline-guaifenesin	• Dyphylline Guaifenesin Medications List	• Oral
Antibody inhibitors	• Omalizumab	• Omalizumab Medications List	• Injection
Anti-interleukin-4	• Dupilumab	• Dupilumab Medications List	• Injection
Anti-interleukin-5	• Benralizumab	• Benralizumab Medications List	• Injection
Anti-interleukin-5	• Mepolizumab	• Mepolizumab Medications List	• Injection
Anti-interleukin-5	• Reslizumab	• Reslizumab Medications List	• Injection
Inhaled steroid combinations	• Budesonide-formoterol	• Budesonide Formoterol Medications	• Inhalation
Inhaled steroid combinations	• Fluticasone-salmeterol	• Fluticasone Salmeterol Medications	• Inhalation
Inhaled steroid combinations	• Fluticasone-vilanterol	• Fluticasone Vilanterol Medications List	• Inhalation
Inhaled steroid combinations	• Formoterol-mometasone	• Formoterol Mometasone Medications List	• Inhalation
Inhaled corticosteroids	• Beclomethasone	• Beclomethasone Medications List	• Inhalation
Inhaled corticosteroids	• Budesonide	• Budesonide Medications List	• Inhalation
Inhaled corticosteroids	• Ciclesonide	• Ciclesonide Medications List	• Inhalation
Inhaled corticosteroids	• Flunisolide	• Flunisolide Medications List	• Inhalation
Inhaled corticosteroids	• Fluticasone	• Fluticasone Medications List	• Inhalation
Inhaled corticosteroids	• Mometasone	• Mometasone Medications List	• Inhalation
Leukotriene modifiers	• Montelukast	• Montelukast Medications List	• Inhalation
Leukotriene modifiers	• Zafirlukast	• Zafirlukast Medications List	• Oral
Leukotriene modifiers	• Zileuton	• Zileuton Medications List	• Oral
Methylxanthines	• Theophylline	• Theophylline Medications List	• Oral

Asthma Reliever Medications

Description	Prescription	Medication Lists	Route
Short-acting, inhaled beta-2 agonists	• Albuterol	• Albuterol Medications List	• Inhalation
Short-acting, inhaled beta-2 agonists	• Levalbuterol	• Levalbuterol Medications List	• Inhalation

Asthma Medication Ratio (AMR)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes - Asthma	
Mild Intermittent Asthma	J45.20-J45.22
Mild Persistent Asthma	J45.30-J45.32
Moderate Persistent Asthma	J45.40-J45.42
Severe Persistent Asthma	J45.50-J45.52
Other and Unspecified Asthma	J45.901-J45.902, J45.909, J45.990, J45.991, J45.998

CPT codes	
ED	99281-99285
Observation	99217-99220
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483

CPT Telephonic and Telehealth codes	
99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205	

Modifier codes for telehealth	
95, GT, 02	

HCPCS codes	
Outpatient	G0402, G0438, G0439, G0463, T1015

Exclusion(s)	
Acute Respiratory Failure, Chronic respiratory Conditions Due to Fumes/Vapors, COPD, Cystic Fibrosis, Emphysema, Obstructive Chronic Bronchitis, Other Emphysema.	

Breast Cancer Screening (BCS)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Q: Which members are included in the sample?

A: Women 50 to 74 years of age who had one or more mammograms to screen for breast cancer any time on or between 10/1/2019 - 12/31/2021.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: *Evidence from claim/encounter data:*

- Screening Mammography between 10/1/2019 - 12/31/2021
- Digital Breast Tomosynthesis between 10/1/2019 - 12/31/2021

Q: How to improve score for this HEDIS® measure?

- A:**
- ☑ Use of complete and accurate Value Set Codes
 - ☑ Timely submission of claim/encounter data
 - ☑ Note that mammograms do not need prior authorization and share list of nearby contracted imaging/ mammography centers with member
 - ☑ Educate female members about the importance of early detection, address common barriers/fears, and encourage testing
 - ☑ Proper coding or documentation of mastectomy either bilateral or unilateral – *to assist in excluding member from the HEDIS® sample. See below for exclusion criteria:*
 - ☑ Exclusions (required): Palliative Care

Exclusions for Breast Cancer Screening: (Use designated Value Set Code for each)

Any of the following meet criteria for bilateral mastectomy:

- Bilateral Mastectomy
- Unilateral Mastectomy with a bilateral modifier

Breast Cancer Screening (BCS)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Q: How to improve score for this HEDIS® measure?

- Two unilateral mastectomies with service dates 14 days or more apart
- Unilateral mastectomy with right-side modifier with same date of service
- Unilateral mastectomy with left-side modifier with same date of service

Note: Biopsies, breast ultrasounds and MRIs are not appropriate methods for breast cancer screening.

Breast Cancer Screening (BCS)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

N/A

CPT codes

Mammography	77055-77057, 77061-77063, 77065-77067
-------------	---------------------------------------

HCPCS codes

Mammography	G0202, G0204, G0206
-------------	---------------------

Exclusion(s)

Absence of Left Breast, Absence of Right Breast, Acute Inpatient, Advanced Illness, Bilateral, Mastectomy, Frailty, History of Bilateral Mastectomy, Observation, Outpatient, Unilateral Mastectomy, Palliative Care.

Controlling High Blood Pressure (CBP)

State Medicaid Auto-Assignment

State Medicaid MPL (must achieve 50th percentile or greater)

NCQA Accreditation - Medicaid

NCQA Accreditation - Medicare (CMC)

Cal Medi-Connect (CMC) Quality Performance Withhold

Q: Which members are included in the sample?

A: Members 18-85 years of age who had at least two visits on different dates of service with a diagnosis of hypertension (HTN) on or between January 1, 2020 and June 30, 2021 whose BP was adequately controlled (<140/90 mm Hg) in 2021.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: Notation of the lowest systolic and lowest diastolic BP reading from the most recent BP notation in the medical record in 2021. (*Note: ALWAYS recheck BP if initial reading is at or > 140/90 mm Hg*)
BP reading must occur on or after the date when the second diagnosis of hypertension occurred.
BP readings taken and reported by member using any digital device and reported or transmitted to the provider are acceptable.

Q: What type of medical record is acceptable?

A: All progress notes in 2021

Controlling High Blood Pressure (CBP)

State Medicaid Auto-Assignment

State Medicaid MPL (must achieve 50th percentile or greater)

NCQA Accreditation - Medicaid

NCQA Accreditation - Medicare (CMC)

Cal Medi-Connect (CMC) Quality Performance Withhold

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Submission of services rendered during a telephone visit, e-visit, or virtual check-in meet criteria.
- ☑ Ensure presence of all components in the medical record documentation
- ☑ Submit any documentation with ESRD, Pregnancy, Kidney transplant or dialysis - *documentation will assist in excluding members from the HEDIS® sample*
- ☑ Exclusion (optional): Female members with diagnosis of pregnancy in 2021.
- ☑ Exclusion (required): Palliative Care
- ☑ Exclusion (required): For Medicare - members 66 years and older living in long term in institutional settings

Controlling High Blood Pressure (CBP)

State Medicaid Auto-Assignment

State Medicaid MPL (must achieve 50th percentile or greater)

NCQA Accreditation - Medicaid

NCQA Accreditation - Medicare (CMC)

Cal Medi-Connect (CMC) Quality Performance Withhold

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

Essential Hypertension	I10
Diabetes	Refer to Diabetes Value Set

CPT codes

Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483	
CPT II codes	3074F—Systolic <130 3075F—Systolic 130-139 3078F—Diastolic <80	3079F—Diastolic 80-89 3077F—Systolic 140 or greater 3080F—Diastolic 90 or greater

CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205.
--

CPT Modifier codes for telehealth

95, GT, 02

HCPCS codes

Outpatient	G0402, G0438, G0439, G0463, T1015
------------	-----------------------------------

Exclusion(s)

Acute Inpatient, Palliative Care, Advanced Illness, ESRD, ESRD Obsolete, Frailty, Inpatient Stay, Kidney, Transplant, Non-acute Inpatient Stay, Observation, Outpatient, Pregnancy.

Cervical Cancer Screening (CCS)

State Medicaid Auto-Assignment

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation - Medicaid

Q: Which members are included in the sample?

A: The percentage of women 21-64 years of age who were screened for cervical cancer using either of the following criteria:

- ☒ Women 21-64 years of age who had cervical cytology performed within 2019, 2020, or 2021.
- ☒ Women 30-64 years of age who had cervical high- risk human papillomavirus (hrHPV) testing performed within 2017, 2018, 2019, 2020 or 2021.
- ☒ Women 30-64 years of age who had cervical cytology/high-risk human papillomavirus (hrHPV) contesting within 2017, 2018, 2019, 2020 or 2021

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: Documentation must include both of the following criteria:

- ☒ a note indicating the date test was performed, *and*
- ☒ the result or finding

Q: What type of medical record is acceptable?

A: Acceptable document:

- ☒ Cervical cytology report/HPV report
- ☒ Chronic Problem List with documentation of Pap Smear with or without HPV, must include date and result
- ☒ Progress note or consultation- notation of date and result of Pap Smear/HPV testing.
- ☒ Documentation that members with history of hysterectomy with no residual cervix, cervical agenesis or acquired absence of cervix meets exclusion (optional) criteria.
- ☒ Any of the following documentation meets criteria:
 1. "Complete", "Total", or "Radical" (abdominal, vaginal or unspecified)
 2. "vaginal hysterectomy"
 3. "vaginal pap smear" in conjunction with documentation of "hysterectomy"
 4. "hysterectomy" in combination with documentation that the patient no longer needs pap testing/ cervical cancer screening.

Cervical Cancer Screening (CCS)

State Medicaid Auto-Assignment

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation - Medicaid

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Use of complete and accurate Value Set Codes
- ☒ Timely submission of claim/encounter data
- ☒ Ensure proper documentation in medical record
- ☒ Request results of screenings be sent to you if done at OB/GYN visit
- ☒ Exclusion (required): Palliative Care
- ☒ Exclusion (optional): Hysterectomy with no residual cervix, cervical agenesis, acquired absence of cervix, or vaginal hysterectomy

Cervical Cancer Screening (CCS)

State Medicaid Auto-Assignment

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation - Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

N/A

CPT codes

Cervical Cytology

88141-88143, 88147, 88148, 88150, 88152-88154,
88164-88167, 88174, 88175

HPV Tests

87620-87622, 87624, 87625

HCPCS codes

Cervical Cytology

G0123, G0124, G0141, G0143-G0145, G0147, G0148,
P3000, P3001, Q0091

HPV Tests

G0476

Exclusion(s)

Absence of Cervix, Palliative Care

Comprehensive Diabetes Care (CDC)

State Medicaid Auto-Assignment (HbA1c Testing)
State Medicaid MPL (must achieve 50th percentile or greater)
Pay-for-Performance (P4P)
NCQA Accreditation – Medicaid
NCQA Accreditation – Medicare (CMC)

Q: Which members are included in the sample?

A: Members 18-75 years of age with diabetes (Type 1 & 2) who had *each* of the following:

- ☒ Hemoglobin A1c (HbA1c) testing in 2021 (P4P)
- ☒ HbA1c Control (<8.0%) (P4P)
- ☒ HbA1c Poor Control (>9.0%)
- ☒ Retinal eye exam in 2020 or 2021 (P4P)
- ☒ Medical attention for nephropathy in 2021 (P4P)
- ☒ Blood pressure (BP) control (<140/90 mmHg) in 2021

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: Hemoglobin A1c (HbA1c) Testing and Control in 2021

- Date of the most recent HbA1c test and the result
- Glycohemoglobin, glycated hemoglobin, and glycosylated hemoglobin are acceptable HbA1c tests

Medical Attention for Nephropathy in 2021

- Urine microalbumin test with the date performed, and result/finding
- Evidence of nephropathy (e.g., renal transplant, ESRD, visit to nephrologist)
- Any urine protein testing or monitoring in 2021 (positive or negative result)
- Evidence of ACE inhibitor/ARB therapy

Blood Pressure (BP) Control (<140/90 mmHg)

- The most recent BP reading during an outpatient visit or a nonacute inpatient encounter in 2021 (For multiple blood pressure reading taken on the same day use the lowest systolic and lowest diastolic BP. ALWAYS recheck BP if initial reading is at or > 140/90 mm Hg)
- BP readings taken and reported by member using any digital device and reported or transmitted to the provider are acceptable.

Note: BP reading taken by the member using a non-digital device such as with a manual blood pressure cuff and a stethoscope DOES NOT MEET CRITERIA.

Comprehensive Diabetes Care (CDC)

State Medicaid Auto-Assignment (HbA1c Testing)
State Medicaid MPL (must achieve 50th percentile or greater)
Pay-for-Performance (P4P)
NCQA Accreditation – Medicaid
NCQA Accreditation – Medicare (CMC)

Q: What documentation is needed in the medical record?

Retinal Eye Exam

- A retinal or dilated eye exam by an eye care professional (optometrist or ophthalmologist) in 2021
- A negative retinal or dilated eye exam (negative for retinopathy) by an eye care professional in 2020
- Bilateral eye enucleation anytime during the member's history through December 31, 2021
- A note or letter from an ophthalmologist, optometrist, PCP or other healthcare professional indicating that an ophthalmoscopic exam was completed by an eye care professional, the date when the procedure was performed and the results
- A chart or photograph of retinal abnormalities indicating the date when the fundus photography was performed and evidence that an eye care professional reviewed the results

Note: Notation limited to a statement that indicates "diabetes without complications" does not meet criteria.

Q: What type of document is acceptable?

A:

- ☑ Progress notes
- ☑ Health Maintenance Log
- ☑ Lab reports
- ☑ Eye exam report from eye care professional (optometrist or ophthalmologist)
- ☑ Nephrology consult report
- ☑ Medication list
- ☑ Blood Pressure Log from the medical record
 - Blood Pressure reading given to provider during telephone visit, e-visits, and virtual check-ins are appropriate.

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Use of complete and accurate Value Set Codes.
- ☑ Timely submission of claim/encounter data
- ☑ Review diabetes services needed at each office visit
- ☑ HbA1c control – schedule regular follow-up with patients to monitor changes and adjust therapies as needed
- ☑ BP control – measure and document BP at each office visit and if elevated (>140/90), measure BP again at end of the visit

Comprehensive Diabetes Care (CDC)

State Medicaid Auto-Assignment (HbA1c Testing)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Ensure proper documentation in medical record. For example:
 - Coding is for *diabetic* retinal eye exam vs. general retinal eye exam
 - Date, time, and result of each BP taken
- ☑ Exclusion (required) Palliative Care
- ☑ Exclusion (optional) Polycystic Ovarian Syndrome (PCOS)

Note: Members who did not have a diagnosis of diabetes, in any setting and who had a diagnosis of gestational diabetes and steroid-induced diabetes, in any setting in 2020 or 2021 can be excluded from the HEDIS® sample.

Comprehensive Diabetes Care (CDC)

State Medicaid Auto-Assignment (HbA1c Testing)
 State Medicaid MPL (must achieve 50th percentile or greater)
 Pay-for-Performance (P4P)
 NCQA Accreditation – Medicaid
 NCQA Accreditation – Medicare (CMC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes	
Diabetes Diagnosis	Refer to Diabetes Value Set
CPT codes	
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483
Diabetic Retinal Screening	67028, 67030, 67031, 67036, 67039-67043, 67101, 67105, 67107, 67108, 67110, 67112, 67113, 67121, 67141, 67145, 67208, 67210, 67218, 67220, 67221, 67227, 67228, 92002, 92004, 92012, 92014, 92018, 92019, 92134, 92225-92228, 92230, 92235, 92240, 92250, 92260, 99203-99205, 99213-99215, 99242-99245
Urine Protein Tests	81000-81003, 81005, 82042-82044, 84156
HbA1c Tests	83036, 83037
CPT Telephonic and Telehealth codes	
99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205	
CPT Modifier codes for telehealth	
95, GT, 02	
BP Testing	3074F, 3075F, 3077F, 3078F, 3079F, 3080F
Diabetic Retinal Screening with Eye Care Professional	2022F, 2024F, 2026F
Diabetic Retinal Screening Negative	3072F

Comprehensive Diabetes Care (CDC)

State Medicaid Auto-Assignment (HbA1c Testing)
State Medicaid MPL (must achieve 50th percentile or greater)
Pay-for-Performance (P4P)
NCQA Accreditation – Medicaid
NCQA Accreditation – Medicare (CMC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

CPT II codes

Urine Protein Tests	3060F, 3061F, 3062F
HbA1c	3044F, 3046F, 3051F, 3052F
Nephropathy Treatment	3066F, 4010F

HCPCS codes

Diabetic Retinal Screening: S0620, S0621, S3000

Exclusion(s)

Palliative Care, Polycystic Ovarian Syndrome, Advanced Illness, Diabetes Exclusions, Frailty.

Chlamydia Screening in Women (CHL)

Pay-for-Performance (P4P)
NCQA Accreditation - Medicaid

Q: Which members are included in the sample?

A: Women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia in **2021**.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation in the medical record is acceptable?

A: *None*. This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence from claim/encounter data

- One chlamydia test in **2021**

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ For all those on birth control pills, make chlamydia screening a standard lab
- ☑ Remember that chlamydia screening can be performed through a simple urine test-offer this as an option for your members
- ☑ Proper coding or documentation will assist in excluding members from the HEDIS® sample
- ☑ Exclude members based on a pregnancy test alone **and** who meet either of the following:
 - A pregnancy test in 2021 **and** a prescription for isotretinoin (Retinoid) on the date of pregnancy test or the 6 days after the pregnancy test
 - A pregnancy test in 2021 **and** an x-ray on the date of the pregnancy test or the 6 days after the pregnancy test

Chlamydia Screening in Women (CHL)

Pay-for-Performance (P4P)
NCQA Accreditation - Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

Refer to Pregnancy Value Set
Refer to Sexual Activity Value Set

CPT codes

Chlamydia Tests	87110, 87270, 87320, 87490-87492, 87810
Pregnancy Tests	81025, 84702, 84703
Sexual Activity	Refer to Sexual Activity Value Set

HCPCS codes

Sexual Activity	G0101, G0123, G0124, G0141, G0143-G0145, G0147, G0148, H1000, H1001, H1003-H1005, P3000, P3001, Q0091, S0199, S4981, S8055
-----------------	--

Exclusion(s)

Diagnostic radiology and Pregnancy Tests.

Childhood Immunization Status (CIS)

State Medicaid Auto - Assignment (Combo 3)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation - Medicaid

Q: Which members are included in the sample?

A: Children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV); one measles, mumps and rubella (MMR); three haemophilus influenza type B (HiB); three hepatitis B (HepB), one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (HepA); two or three rotavirus (RV); and two influenza (flu) vaccines **by their second birthday**. LAIV(Influenza) vaccination must occur on the child's second birthday.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: Documentation must include any of the following:

*Specific for: **MMR, HepB, VZV, and HepA***

- ☒ Evidence of the antigen or combination vaccine (include specific dates)
- ☒ Documented history of the illness
- ☒ A seropositive test result

*Specific for: **DTaP, HiB, IPV, PCV, rotavirus, and influenza***

- ☒ Evidence of the antigen or combination vaccine (include specific dates)

OR

- ☒ Notation indicating contraindication for a specific vaccine:
(Use designated Value Set Codes for each)

Any Particular Vaccine	<ul style="list-style-type: none">Anaphylactic reaction to the vaccine or its components
DTaP	<ul style="list-style-type: none">Encephalopathy with a vaccine adverse-effect code
MMR, VZV, and Influenza	<ul style="list-style-type: none">ImmunodeficiencyHIVAnaphylactic reaction to neomycinLymphoreticular cancer, Multiple Myeloma, or Leukemia
Rotavirus	<ul style="list-style-type: none">Severe combined immunodeficiencyHistory of intussusception

Childhood Immunization Status (CIS)

State Medicaid Auto - Assignment (Combo 3)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation - Medicaid

Q: What documentation is needed in the medical record?

OR

- ☒ Notation indicating contraindication for a specific vaccine:
(Use designated Value Set for each)

IPV	Anaphylactic reaction to streptomycin, polymyxin B or neomycin
Hepatitis B	Anaphylactic reaction to common baker's yeast

Q: What type of medical record is acceptable?

A: One or more of the following:

- ☒ Certificate of immunization including specific dates and types of vaccines
- ☒ Hospital record with notation of HepB
- ☒ Immunization Record and Health History Form
- ☒ Health Maintenance Form
- ☒ Lab report for seropositive test
- ☒ Print out of LINK/CAIR registry
- ☒ Progress/office notes with notations of vaccines given
- ☒ Medical History Form

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Upload immunizations on to California Immunizations Registry (<http://cairweb.org>)
- ☒ Use the Childhood and Adolescent Wellness Flyers for Providers as a guideline of recommended health services for certain age groups (http://www.lacare.org/sites/default/files/LA1401_0815.pdf)
- ☒ Educate parents about the importance of timely vaccinations and share the immunization schedule
- ☒ Use of complete and accurate Value Set Codes
- ☒ Timely submission of claim/encounter data
- ☒ Ensure proper documentation of dates and types of immunizations, test results, history of illness, or contraindication for a specific vaccine

Childhood Immunization Status (CIS)

State Medicaid Auto - Assignment (Combo 3)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation - Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 PC code	
Newborn Hepatitis B	3E0234Z

CPT codes	
DTap Vaccine	90698, 90700, 90721, 90723
Haemophilus Influenzae Type B (HiB) Vaccine	90644-90648, 90698, 90721, 90748
Hepatitis A Vaccine	90633
Hepatitis B Vaccine	90723, 90740, 90744, 90747, 90748
Inactivated Polio Vaccine (IPV)	90698, 90713, 90723
Influenza Vaccine	90655, 90657, 90661, 90662, 90673, 90685-90688
Measles Vaccine	90705
Measles, Mumps and Rubella Vaccine	90707, 90710
Measles/Rubella Vaccine	90708
Mumps Vaccine	90704
Pneumococcal Conjugate Vaccine	90670
Rotavirus Vaccine (2 dose)	90681
Rotavirus Vaccine (3 dose)	90680
Rubella Vaccine	90706
Varicella Zoster Vaccine	90710, 90716

Childhood Immunization Status (CIS)

State Medicaid Auto - Assignment (Combo 3)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation - Medicaid

HCPCS codes

Influenza	G0008
Pneumococcal	G0009
Hepatitis B Vaccine	G0010

Exclusion(s)

Anaphylactic Reaction Due to Vaccination, Disorders of Immune System, Encephalopathy Due to Vaccination, HIV, Intussusception, Malignant Neoplasm of Lymphatic Tissue, Severe Combined Immunodeficiency, Vaccine Causing Adverse Effect.

Care for Older Adults (COA)

Q: Which members are included in the sample?

A: Adults 66 years and older who had *each* of the following in **2021**:

- ☒ Advance care planning
- ☒ Medication review
- ☒ Functional status assessment
- ☒ Pain assessment

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A:

- ☒ **Advanced Care Planning** – evidence must include either the presence of advanced care plan in the medical record *or* documentation of advance care planning discussion with the provider and the date when it was discussed
- ☒ **Evidence of Medication Review** – must include medication list in the medical record, and evidence of a medication review and the date when it was performed *or* notation that the member is not taking any medication and the date when it was noted
- ☒ **Evidence of Functional Status Assessment** – documentation must include evidence of functional status assessment *and* the date when it was performed
- ☒ **Evidence of Pain Assessment** – documentation must include evidence of a pain assessment (may include positive or negative findings for pain) and the date when it was performed

Care for Older Adults (COA)

Q: What type of medical record is acceptable?

A:

Advanced Care Planning:

- ☒ Advance Directives
- ☒ Actionable medical orders
- ☒ Copy of Living Wills, Medical Power of Attorney
- ☒ Copy of documentation of surrogate decision maker
- ☒ Notation of advance care planning discussion with a provider in 2021
- ☒ Evidence of oral statements noted in the medical record in 2021
- ☒ Notation that a member declined to discuss advanced care planning in 2021

Medication Review:

- ☒ Current medication list in 2021
- ☒ Notation of medication review in 2021
- ☒ Date and notation that the member is not taking any medication in 2021

Note: Medication Review does not require member to be present.

Functional Status Assessment:

- ☒ Progress notes, IHSS forms, HRA forms, AWE form
- ☒ Notation that Activities of Daily Living (ADL) were assessed or that at least 5 of the following were assessed: bathing, dressing, eating, transferring [e.g., getting in and out of chairs], using toilet, walking
- ☒ Notation that Instrumental Activities of Daily Living (IADL) were assessed or at least 4 of the following were assessed: shopping for groceries, driving or using public transportation, using the telephone, meal preparation, housework, home repair, laundry, taking medications, handling finances
- ☒ Result of assessment using a standardized functional status assessment tool

Care for Older Adults (COA)

Q: What type of medical record is acceptable?

A: Pain Assessment:

- ☑ Progress notes – notation of a pain assessment (which may include positive or negative findings for pain)
- ☑ Result of assessment using a standardized pain assessment tool
- ☑ Numeric rating scales (verbal or written)
- ☑ Pain Thermometer
- ☑ Pictorial Pain Scales
- ☑ Visual Analogue Scale
- ☑ Brief Pain Inventory
- ☑ Chronic Pain Grade
- ☑ PROMIS Pain Intensity Scale
- ☑ Pain Assessment in Advanced Dementia (PAINAD) Scale

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Submission of services rendered during a telephone visit, e-visit, or virtual check-in meet criteria.
- ☑ Ensure presence of all components in the medical record documentation
- ☑ Timely submission of complete and accurate AWE Forms
- ☑ Exclude services provided in an acute inpatient setting

Care for Older Adults (COA)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 Codes	
N/A	
CPT Codes	
Advance Care Planning	99497, 99483
Medication Review	90863, 99483, 99605, 99606
TCM 14 day	99495
TCM 7 day	99496
CPT Telephonic and Telehealth codes	
99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205	
CPT Modifier codes for telehealth	
95, GT, 02	
CPT II Codes	
Pain Assessment	1125F, 1126F
Advance Care Planning	1123F, 1124F, 1157F, 1158F
Medication List	1159F
Medication Review	1160F
Functional Status Assessment	1170F

Care for Older Adults (COA)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

HCPCS codes

Medication List	G8427
Advance Care Planning	S0257

Exclusion(s)

Acute Inpatient, Acute Inpatient POS

Colorectal Cancer Screening (COL)

NCQA Accreditation - Medicare

Q: Which members are included in the sample?

A: Members 50-75 years of age who had one or more appropriate screenings for colorectal cancer.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: Documentation in the medical record must include a note indicating the **date** the colorectal cancer screening was performed. Appropriate screenings are defined by **any** of the following:

- ☒ Fecal Occult Blood Test in **2020 to 2021**; guaiac (gFOBT) or immunochemical (FIT)
- ☒ Flexible sigmoidoscopy performed in **2017, 2018, 2019, 2020, or 2021**
- ☒ Colonoscopy in **2021 or within 9 years prior to 2021**
- ☒ CT colonography performed in **2017, 2018, 2019, 2020, or 2021**
- ☒ FIT-DNA Test or Cologuard report in **2019, 2020, or 2021**

Q: What type of medical record is acceptable?

A: One or more of the following:

- | | |
|---|--|
| <input checked="" type="checkbox"/> Health Maintenance Form | <input checked="" type="checkbox"/> Pathology report without indicating the type of screening but has evidence that the scope advanced beyond the splenic flexure or sigmoid colon |
| <input checked="" type="checkbox"/> Progress notes/Office visits notes | <input checked="" type="checkbox"/> Medical History Forms |
| <input checked="" type="checkbox"/> Problem List | <input checked="" type="checkbox"/> X-ray Reports |
| <input checked="" type="checkbox"/> Laboratory/Pathology Reports | <input checked="" type="checkbox"/> GI Consults/ Reports/ Flowcharts |
| <input checked="" type="checkbox"/> Pathology report that indicates the type of screening (e.g., colonoscopy or flexible sigmoidoscopy) | <input checked="" type="checkbox"/> Complete Physical Examination Form |

Note: Do not count digital rectal exams (DRE), FOBT tests performed in an office setting or performed on a sample collected via DRE.

Colorectal Cancer Screening (COL)

NCQA Accreditation - Medicare

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Prior to each visit for members 50 years and older, review chart to determine if COL screening has been completed, if not, discuss options with member, as colonoscopy every 10 years and stool testing done yearly are shown to have similar effectiveness in identifying colon cancer
- ☑ Request a supply of stool screening test kits from your contracted lab(s) to have on hand to share with members when at office visits
- ☑ If a member had a colonoscopy, the provider's office should ask the member for a copy of the report or the rendering provider's contact information to request the report and save a copy in the member's medical record
- ☑ Timely submission of claim/encounter data
- ☑ Ensure presence of all components in the medical record documentation
- ☑ *Exclude members with diagnosis of colorectal cancer or total colectomy*
- ☑ *Exclusions: Palliative care, hospice care, advanced illness, and frailty*

Colorectal Cancer Screening (COL)

NCQA Accreditation - Medicare

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

N/A

CPT codes

FOBT	82270, 82274
Flexible Sigmoidoscopy	45330-45335, 45337-45342, 45345-45347, 45349, 45350
Colonoscopy	44388-44394, 44397, 44401-44408, 45355, 45378-45393, 45398
CT Colonography	74261-74263
FIT-DNA	81528

HCPCS codes

FOBT	G0328
Flexible Sigmoidoscopy	G0104
Colonoscopy	G0105, G0121
Colorectal Cancer (PET scan)	G0213-G0215, G0231
FIT-DNA	G0464

Exclusion(s)

Advanced Illness, Palliative Care, Colorectal Cancer, Frailty, Hospice, Total Colectomy.

Cardiac Rehabilitation (CRE)

Q: Which members are included in the sample?

- A:** Members 18 years and older, who attended cardiac rehabilitation following a qualifying cardiac event, including myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, heart and heart/lung transplantation or heart valve repair/replacement. Four rates are reported:
- *Initiation.* The percentage of members who attended 2 or more sessions of cardiac rehabilitation within 30 days after a qualifying event.
 - *Engagement 1.* The percentage of members who attended 12 or more sessions of cardiac rehabilitation within 90 days after a qualifying event.
 - *Engagement 2.* The percentage of members who attended 24 or more sessions of cardiac rehabilitation within 180 days after a qualifying event.
 - *Achievement.* The percentage of member who attended 36 or more sessions of cardiac rehabilitation within 180 days after a qualifying event.

Q: What codes are used?

- A:** Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

- A:** *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: How to improve score for this HEDIS® measure?

- A:**
- ☒ Use of complete and accurate Value Set Codes
 - ☒ Timely submission of claim/encounter data

Cardiac Rehabilitation (CRE)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

CPT Codes

99201-99205, 99211-99215, 99241-99244

CPT Telephonic and Telehealth Codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

CPT Modifier Codes for Telehealth

95, GT, 02

HCPCS Codes

G0402, G0438, G0439, G0463, T1015

Exclusion(s)

Myocardial infarction, old myocardial infarction or Hospice setting or Hospice care.

Appropriate Testing for Children with Pharyngitis (CWP)

Pay-for-Performance (P4P)

NCQA Accreditation - Medicaid

Q: Which members are included in the sample?

A: Children with Members 3 years and older, who were diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode (7/1/2020 - 6/30/2021) during any outpatient or ED visit.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence of claim/encounter data:

- ☒ Date of service for an outpatient or ED visit with a diagnosis of pharyngitis
- ☒ Throat culture lab report
- ☒ Date and result of strep test with a diagnosis of pharyngitis
- ☒ Antibiotic prescription for the episode

Appropriate Testing for Children with Pharyngitis (CWP)

Pay-for-Performance (P4P)

NCQA Accreditation - Medicaid

Antibiotic Medications:

Description	Prescription		
Aminopenicillins	<ul style="list-style-type: none">• Amoxicillin	<ul style="list-style-type: none">• Ampicillin	
Beta lactamase inhibitors	<ul style="list-style-type: none">• Amoxicillin-clavulanate		
First generation cephalosporins	<ul style="list-style-type: none">• Cefadroxil• Cefazolin	<ul style="list-style-type: none">• Cephalexin	
Folate antagonist	<ul style="list-style-type: none">• Trimethoprim		
Lincomycin derivatives	<ul style="list-style-type: none">• Clindamycin		
Macrolides	<ul style="list-style-type: none">• Azithromycin• Clarithromycin• Erythromycin	<ul style="list-style-type: none">• Erythromycin ethylsuccinate• Erythromycin lactobionate• Erythromycin stearate	
Miscellaneous antibiotics	<ul style="list-style-type: none">• Erythromycin-sulfisoxazole		
Natural penicillins	<ul style="list-style-type: none">• Penicillin G potassium• Penicillin G sodium	<ul style="list-style-type: none">• Penicillin V potassium	
Penicillinase-resistant penicillins	Dicloxacillin		
Quinolones	<ul style="list-style-type: none">• Ciprofloxacin• Levofloxacin	<ul style="list-style-type: none">• Moxifloxacin• Ofloxacin	
Second generation cephalosporins	<ul style="list-style-type: none">• Cefaclor• Cefprozil	<ul style="list-style-type: none">• Cefuroxime	
Sulfonamides	<ul style="list-style-type: none">• Sulfamethoxazole-trimethopim		
Tetracyclines	<ul style="list-style-type: none">• Doxycycline• Minocycline	<ul style="list-style-type: none">• Tetracycline	
Third generation cephalosporins	<ul style="list-style-type: none">• Cefdinir• Cefixime	<ul style="list-style-type: none">• Cefpodoxime• Ceftibuten	<ul style="list-style-type: none">• Cefditoren• Ceftriaxone

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Use of complete and accurate Value Set Codes
- ☒ Timely submission of claim/encounter data
- ☒ Ensure presence of all components in the medical record documentation

Appropriate Testing for Children with Pharyngitis (CWP)

Pay-for-Performance (P4P)

NCQA Accreditation - Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

Pharyngitis	J02.0, J02.8, J02.9, J03.00, J03.01, J03.80, J03.81, J03.90, J03.91
-------------	---

CPT codes

Group A Strep Tests	87070, 87071, 87081, 87430, 87650-87652, 87880
---------------------	--

Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483
------------	--

CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

CPT Modifier codes for telehealth

95, GT, 02

HCPCS codes

Outpatient	G0402, G0438, G0439, G0463, T1015
------------	-----------------------------------

Exclusion(s)

Hospice, Inpatient Stay

Use of High-Risk Medications in Older Adults (DAE)

NCQA Accreditation – Medicare (CMC)

Q: Which members are included in the sample?

A: Medicare members 67 years and older who had:

- At least one dispensing event for a high-risk medication
- At least two dispensing events for the same high-risk-medication

*For both rates, a lower rate indicates better performance.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of documentation is acceptable?

A: Evidence from a claim/encounter data:

- ☒ One or two dispensing event(s) for a high-risk medication in 2021

Use of High-Risk Medications in Older Adults (DAE)

NCQA Accreditation – Medicare (CMC)

High-Risk Medications

Description	Prescription	Medication Lists	Description	Prescription	Medication Lists
Anticholinergics, first-generation antihistamines	<ul style="list-style-type: none"> Brompheniramine Carbinoxamine Chlorpheniramine Clemastine Cyproheptadine Dexbrompheniramine Dexchlorpheniramine Diphenhydramine (oral) Dimenhydrinate Doxylamine Hydroxyzine Mecizine Promethazine Pyrilamine Triprolidine 	<ul style="list-style-type: none"> Brompheniramine Medications List Carbinoxamine Medications List Chlorpheniramine Medications List Clemastine Medications List Cyproheptadine Medications List Dexbrompheniramine Medications List Dexchlorpheniramine Medications List Diphenhydramine Medications List Dimenhydrinate Medications List Doxylamine Medications List Hydroxyzine Medications List Mecizine Medications List Promethazine Medications List Pyrilamine Medications List Triprolidine Medications List 	Central nervous system, vasodilators	<ul style="list-style-type: none"> Ergoloid mesylates Isoxsuprine 	<ul style="list-style-type: none"> Ergoloid Mesylates Medications List Isoxsuprine Medications List
			Central nervous system, other	<ul style="list-style-type: none"> Meprobamate 	<ul style="list-style-type: none"> Meprobamate Medications List
			Endocrine system, estrogens with or without progestins; include only oral and topical patch products	<ul style="list-style-type: none"> Conjugated estrogen Esterified estrogen Estradiol Estropipate 	<ul style="list-style-type: none"> Conjugated Estrogens Medications List Esterified Estrogens Medications List Estradiol Medications List Estropipate Medications List
			Endocrine system, sulfonylureas, long-duration	<ul style="list-style-type: none"> Chlorpropamide Glimepiride Glyburide 	<ul style="list-style-type: none"> Chlorpropamide Medications List Glimepiride Medications List Glyburide Medications List
Anticholinergics, anti-Parkinson agents	<ul style="list-style-type: none"> Benzotropine (oral) Trihexyphenidyl 	<ul style="list-style-type: none"> Benzotropine Medications List Trihexyphenidyl Medications List 	Endocrine system, other	<ul style="list-style-type: none"> Desiccated thyroid MeGESTROL 	<ul style="list-style-type: none"> Desiccated Thyroid Medications List MeGESTROL Medications List
Antispasmodics	<ul style="list-style-type: none"> Atropine (exclude ophthalmic) Belladonna alkaloids Chlordiazepoxide-clidinium Dicyclomine Hyoscyamine Methscopolamine Propantheline Scopolamine 	<ul style="list-style-type: none"> Atropine Medications List Belladonna Medications List Chlordiazepoxide Clidinium Medications List Dicyclomine Medications List Hyoscyamine Medications List Methscopolamine Medications List Propantheline Medications List Scopolamine Medications List 	Nonbenzodiazepine hypnotics	<ul style="list-style-type: none"> Eszopiclone Zaleplon Zolpidem 	<ul style="list-style-type: none"> Nonbenzodiazepine Hypnotics Medications List
Antithrombotic	<ul style="list-style-type: none"> Dipyridamole, oral short- acting 	<ul style="list-style-type: none"> Dipyridamole Medications List 	Pain medications, skeletal muscle relaxants	<ul style="list-style-type: none"> Carisoprodol Chlorzoxazone Cyclobenzaprine Metaxalone Methocarbamol Orphenadrine 	<ul style="list-style-type: none"> Carisoprodol Medications List Chlorzoxazone Medications List Cyclobenzaprine Medications List Metaxalone Medications List Methocarbamol Medications List Orphenadrine Medications List
Cardiovascular, alpha agonists, central	<ul style="list-style-type: none"> Guanfacine Methyldopa 	<ul style="list-style-type: none"> Guanfacine Medications List Methyldopa Medications List 	Pain medications, other	<ul style="list-style-type: none"> Indomethacin Ketorolac, includes parenteral Meperidine 	<ul style="list-style-type: none"> Indomethacin Medications List Ketorolac Medications List
Cardiovascular, other	<ul style="list-style-type: none"> Disopyramide Nifedipine, immediate release 	<ul style="list-style-type: none"> Disopyramide Medications List Nifedipine Medications List 			
Central nervous system, antidepressants	<ul style="list-style-type: none"> Amitriptyline Amoxapine Clomipramine Desipramine Imipramine Nortriptyline Paroxetine Protriptyline Trimipramine 	<ul style="list-style-type: none"> Amitriptyline Medications List Amoxapine Medications List Clomipramine Medications List Desipramine Medications List Imipramine Medications List Nortriptyline Medications List Paroxetine Medications List Protriptyline Medications List Trimipramine Medications List 			
Central nervous system, barbiturates	<ul style="list-style-type: none"> Amobarbital Butabarbital Butalbital Pentobarbital Phenobarbital Secobarbital 	<ul style="list-style-type: none"> Amobarbital Medications List Butabarbital Medications List Butalbital Medications List Pentobarbital Medications List Phenobarbital Medications List Secobarbital Medications List 			

Use of High-Risk Medications in Older Adults (DAE)

NCQA Accreditation – Medicare (CMC)

High-Risk Medications

High Risk Medications with Days Supply Criteria

Description	Prescription	Average Daily Dose Criteria	Medication Lists
Anti-Infectives, other	<ul style="list-style-type: none">NitrofurantoinNitrofurantoin macrocrystalsNitrofurantoin macrocrystals-monohydrate	>90 days	<ul style="list-style-type: none">High Risk Anti Infectives Medication List

High-Risk Medications with Daily Average Dose Criteria

Description	Prescription	Average Daily Dose Criteria	Medication Lists
Alpha agonists, central	<ul style="list-style-type: none">Reserpine	>0.1 mg/day	<ul style="list-style-type: none">Reserpine 0.1 mg Medications ListReserpine 0.25 mg Medications List
Cardiovascular, other	<ul style="list-style-type: none">Digoxin	>0.125 mg/day	<ul style="list-style-type: none">Digoxin .05 mg per mL Medications ListDigoxin .0625 mg Medications ListDigoxin .1 mg per mL Medications ListDigoxin .125 mg Medications ListDigoxin .1875 mg Medications ListDigoxin .25 mg Medications ListDigoxin .25 mg per mL Medications List
Tertiary TCAs (as single agent or as part of combination products)	<ul style="list-style-type: none">Doxepin	>6 mg/day	<ul style="list-style-type: none">Doxepin 3 mg Medications ListDoxepin 6 mg Medications ListDoxepin 10 mg Medications ListDoxepin 10 mg per mL Medications ListDoxepin 25 mg Medications ListDoxepin 50 mg Medications ListDoxepin 75 mg Medications ListDoxepin 100 mg Medications ListDoxepin 150 mg Medications List

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Use of complete and accurate Value Set Codes
- ☒ Timely submission of claim/encounter data

Use of High-Risk Medications in Older Adults (DAE)

NCQA Accreditation – Medicare (CMC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

CPT codes

Outpatient services:

Office/other outpatient services:	99201-99205, 99211-99215
Consultations	99241-99245
Preventive medicine services	99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429

CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

CPT Modifier codes for telehealth

95, GT, 02

HCPCS codes

Outpatient	G0402, G0438, G0439, G0463, T1015
------------	-----------------------------------

Exclusion(s)

Hospice, Palliative Care

Potentially Harmful Drug-Disease Interactions in Older Adults (DDE)

NCQA Accreditation – Medicare (CMC)

Q: Which members are included in the sample?

A: Medicare members 65 years and older who have evidence of an underlying disease, condition or health concern and who were dispensed an ambulatory prescription for a potentially harmful medication, concurrent with or after the diagnosis between January 1, 2020 - December 1, 2021.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Potentially Harmful Drug-Disease Interactions in Older Adults (DDE)

NCQA Accreditation – Medicare (CMC)

Q: What type of documentation is acceptable?

A: Evidence from claim/encounter data for:

- 1 Rate 1: Drug-Disease Interactions- History of Falls and Antiepileptics, Antipsychotics, Benzodiazepines, Nonbenzodiazepine Hypnotics or Antidepressants (SSRIs, Tricyclic Antidepressants and SNRIs)

Potentially Harmful Drugs—History of Falls Medications

Description	Prescription
Antiepileptics	<ul style="list-style-type: none"> Carbamazepine Clobazam Divalproex sodium Ethosuximide Ethotoin Ezogabine Felbamate Fosphenytoin Gabapentin Lacosamide Lamotrigine Levetiracetam Methsuximide Oxcarbazepine Phenobarbital Phenytoin Pregabalin Primidone Rufinamide Tiagabine HCL Topiramate Valproic acid Vigabatrin Zonisamide
SNRIs	<ul style="list-style-type: none"> Desvenlafaxine Duloxetine Levomilnacipran Venlafaxine
SSRIs	<ul style="list-style-type: none"> Citalopram Escitalopram Fluoxetine Fluvoxamine Paroxetine Sertraline

Potentially Harmful Drugs—History of Falls and Dementia Medications

Description	Prescription
Antipsychotics	<ul style="list-style-type: none"> Aripiprazole Asenapine Brexpiprazole Cariprazine Chlorpromazine Clozapine Fluphenazine Haloperidol Iloperidone Loxapine Lurasidone Molindone Olanzapine Paliperidone Perphenazine Pimozide Quetiapine Risperidone Thioridazine Thiothixene Trifluoperazine Ziprasidone
Benzodiazepines	<ul style="list-style-type: none"> Alprazolam Chlordiazepoxide Clonazepam Clorazepate Diazepam Estazolam Flurazepam Lorazepam Midazolam Oxazepam Quazepam Temazepam Triazolam
Nonbenzodiazepine hypnotics	<ul style="list-style-type: none"> Eszopiclone Zaleplon Zolpidem
Tricyclic antidepressants	<ul style="list-style-type: none"> Amitriptyline Amoxapine Clomipramine Desipramine Doxepin (>6 mg) Imipramine Nortriptyline Protriptyline Trimipramine

Potentially Harmful Drug-Disease Interactions in Older Adults (DDE)

NCQA Accreditation – Medicare (CMC)

Q: What type of documentation is acceptable?

- 2 Drug-Disease Interactions- Dementia and Antipsychotics, Benzodiazepines, Nonbenzodiazepine Hypnotics, Tricyclic Antidepressants or Anticholinergic Agents

Dementia Medications

Description	Prescription
Cholinesterase inhibitors	<ul style="list-style-type: none"> • Donepezil • Galantamine • Rivastigmine
Miscellaneous central nervous system agents	<ul style="list-style-type: none"> • Memantine
Dementia combinations	<ul style="list-style-type: none"> • Donepezil-memantine

Potentially Harmful Drugs—Dementia Medications

Description	Prescription
Anticholinergic agents, antiemetics	<ul style="list-style-type: none"> • Prochlorperazine • Promethazine
Anticholinergic agents, antihistamines	<ul style="list-style-type: none"> • Brompheniramine • Carbinoxamine • Chlorpheniramine • Clemastine • Cyproheptadine • Dexbrompheniramine • Dexchlorpheniramine • Dimenhydrinate • Diphenhydramine • Doxylamine • Pyrilamine • Triprolidine • Hydroxyzine • Meclizine
Anticholinergic agents, antispasmodics	<ul style="list-style-type: none"> • Atropine • Belladonna alkaloids • Clidinium- chlordiazepoxide • Dicyclomine • Homatropine • Hyoscyamine • Methscopolamine • Propantheline • Scopolamine
Anticholinergic agents, antimuscarinics (oral)	<ul style="list-style-type: none"> • Darifenacin • Fesoterodine • Flavoxate • Oxybutynin • Solifenacin • Tolterodine • Trosipium
Anticholinergic agents, anti- Parkinson agents	<ul style="list-style-type: none"> • Benztropine • Trihexyphenidyl
Anticholinergic agents, skeletal muscle relaxants	<ul style="list-style-type: none"> • Cyclobenzaprine • Orphenadrine
Anticholinergic agents, SSRIs	<ul style="list-style-type: none"> • Paroxetine
Anticholinergic agents, antiarrhythmic	<ul style="list-style-type: none"> • Disopyramide

Potentially Harmful Drug-Disease Interactions in Older Adults (DDE)

NCQA Accreditation – Medicare (CMC)

3. Rate 3: Drug- Disease Interactions- Chronic Kidney Disease and Cox-2 Selective NSAIDS or Nonaspirin NSAIDs

Cox-2 Selective NSAIDs and Nonaspirin NSAIDs Medications

Description	Prescription			
Cox-2 Selective NSAIDs	<ul style="list-style-type: none">Celecoxib			
Nonaspirin NSAIDs	<ul style="list-style-type: none">Diclofenac potassiumDiclofenac sodiumEtodolacFenoprofenFlurbiprofen	<ul style="list-style-type: none">IbuprofenIndomethacinKetoprofenKetorolacMeclofenamate	<ul style="list-style-type: none">Mefenamic acidMeloxicamNabumetoneNaproxenNaproxen sodium	<ul style="list-style-type: none">OxaprozinPiroxicamSulindacTolmetin

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Use of complete and accurate Value Set Codes
- ☒ Timely submission of claim/encounter data
- ☒ Exclusion (required) Palliative Care

Potentially Harmful Drug-Disease Interactions in Older Adults (DDE)

NCQA Accreditation – Medicare (CMC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

CPT codes	
Hip Fractures	27230, 27232, 27235, 27236, 27238, 27240, 27244-27246, 27248, 27254, 27267-27269, 27767-27769
ESRD	90935, 90937, 90945, 90947, 90997, 90999, 99512, 36800, 36810, 36815, 36819, 36820, 36821, 36831, 36833,
CPT Telephonic and Telehealth codes	
99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205	
CPT Modifier codes for telehealth	
95, GT, 02	
Outpatient	
E&M, office/other outpatient services	99201-99205, 99211-99215
E&M, hospital observation services	99217-99220
E&M, consultations	99241-99245
E&M, preventive medicine services	99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429
ICD10 CM codes	
Dementia	G30.0, G30.1, G30.8, G30.9, G31.83, 290.0, 290.10 - 290.13, 290.20, 290.21, 290.3, 290.40 – 290.43, 290.8, 290.9, 291.2, 292.82, 294.0, 294.10, 294.11, 294.20
ESRD	Z91.15, Z99.2
Fall/Hip Fracture	Refer to Value Set Directory

Potentially Harmful Drug-Disease Interactions in Older Adults (DDE)

NCQA Accreditation – Medicare (CMC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

HCPCS Code	
ESRD	G0257, S9339
Outpatient	G0402, G0438, G0439, G0463, T1015

Exclusion(s)
Palliative Care, Bipolar Disorder, Hospice, Other Bipolar Disorder Psychosis, Schizoaffective Disorder, Schizophrenia, or Seizure Disorder on or between January 1, 2020 and December 1, 2021.

Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)*

* Adapted with financial support from the Centers for Medicare & Medicaid Services (CMS)

Q: Which members are included in the sample?

- A:** Members 12 years of age and older who were screened for clinical depression using a standardized instrument and, if screened positive, received follow-up care.
- Depression Screening- Members who were screened for clinical depression using a standardized instrument.
 - Follow-Up on Positive Screening- Members who received follow-up care within 30 days of positive depression screen finding.

Q: What codes are used?

- A:** Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

- A:** None. This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)*

* Adapted with financial support from the Centers for Medicare & Medicaid Services (CMS)

Q: What type of documentation is acceptable?

A: Evidence from a claim/encounter data:

- Documentation of standardized age appropriate tool for screening clinical depression.
- Documentation of a follow-up care on or 30 days after the date of the first positive screen (31 days total) from any one of the following.
 - a follow-up behavioral health encounter with or without a telehealth modifier including assessment, therapy, collaborative care, medication management, acute care and health encounters
 - a follow up outpatient visit with a diagnosis of depression or other behavioral health condition, with or without telehealth modifier
 - a telephone visit with diagnosis of depression or other behavioral health condition
 - a follow-up with a case manager with documented assessment of depression symptoms
 - dispensed an antidepressant medication

Depression Screening Instrument	A standard assessment instrument that has been normalized and validated for the appropriate patient population. Eligible screening instruments with thresholds for positive findings include:	
	Instruments for Adolescents (12–17 years)	Positive Finding
	Patient Health Questionnaire (PHQ-9) [®]	Total Score ≥10
	Patient Health Questionnaire Modified for Teens (PHQ-9M) [®]	Total Score ≥10
	Patient Health Questionnaire-2 (PHQ-2) ^{®2}	Total Score ≥3
	Beck Depression Inventory-Fast Screen (BDI-FS) ^{®1,2}	Total Score ≥8
	Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)	Total Score ≥17
	Edinburgh Postnatal Depression Scale (EPDS)	Total Score ≥10
	PROMIS Depression	Total Score (T Score) ≥60
	Instruments for Adults (18+ years)	Positive Finding
	Patient Health Questionnaire (PHQ-9) [®]	Total Score ≥10
	Patient Health Questionnaire-2 (PHQ-2) ^{®2}	Total Score ≥3
	Beck Depression Inventory-Fast Screen (BDI-FS) ^{®1,2}	Total Score ≥8
	Beck Depression Inventory (BDI-II)	Total Score ≥20
	Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)	Total Score ≥17
	Duke Anxiety-Depression Scale (DADS) ^{®1}	Total Score ≥30
	Geriatric Depression Scale Short Form (GDS) ²	Total Score ≥5
	Geriatric Depression Scale Long Form (GDS)	Total Score ≥10
	Edinburgh Postnatal Depression Scale (EPDS)	Total Score ≥10
	My Mood Monitor (M-3) [®]	Total Score ≥5
	PROMIS Depression	Total Score (T Score) ≥60
	Clinically Useful Depression Outcome Scale (CUDOS)	Total Score ≥31

¹Proprietary; may be cost or licensing requirement associated with use.

²Brief screening instrument. All other instruments are full-length.

Q: How to improve score for this HEDIS® measure?

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data

Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)*

* Adapted with financial support from the Centers for Medicare & Medicaid Services (CMS)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD 10 Codes:

Depression or Other Behavioral Health Condition:	F01.51, F20.0-F20.5, F20.81, F20.89, F20.9
--	--

CPT Codes:

Behavioral Health Encounter:	90791, 90792, 90832, 90833, 90834, 90836, 90837-90839, 90845-90847, 90849, 90853, 90865, 90867-90870, 90875, 90876, 90880, 90887
Depression Case Management Encounter:	99366
Follow-Up Visit:	98960-98962, 99078, 99201-99205, 99211 – 99215, 99217-99220, 99241 – 99245, 99341 – 99345, 99347 -99350, 99381 – 99387, 99391 – 99397, 99401 – 99404, 99411, 99412,

CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205.

CPT Modifier codes for telehealth

95, GT, 02

HCPSC codes

Depression Case Management Encounter:	T1016, T1017, T2022, T2023, G0463, T1015
---------------------------------------	--

Exclusion(s)

Bipolar Disorder, Depression, Hospice

Follow-Up After Hospitalization for Mental Illness (FUH)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Cal Medi-Connect (CMC) Quality Performance Withhold

Q: Which members are included in the sample?

A: Members 6 years of age and older who were hospitalized for treatment of selected mental illness or intentional self-harm diagnosis and who had a follow-up visit with a mental health provider. Two rates are reported:

1. The percentage of discharges for which the member received follow-up within 30 days after discharge.
2. The percentage of discharges for which the member received follow-up within 7 days after discharge

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: None. This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of documentation is acceptable?

A: Evidence from a claim/encounter data:

- Documentation of a follow-up visit in 2021 with a mental health provider within 7-30 days of discharge from hospitalization for treatment of mental illness
- Documentaion of a follow-up:
 - Visits in behavioral health settings.
 - Telephone Visits
- Include all discharges on or between January 1 and December 1 of 2021
*Follow-up visits that occur on the date of discharge do not count.

Follow-Up After Hospitalization for Mental Illness (FUH)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Cal Medi-Connect (CMC) Quality Performance Withhold

Q: How to improve score for this HEDIS® measure?

A:

- Use of complete and accurate Value Set Codes
- Timely submission of claim/encounter data
- Document hospice care readmission/direct transfer to acute setting for exclusion from the eligible population
- Mental Health Provider: A practitioner who provides mental health services and meets any of the following criteria:
 - o An MD or (DO) who is certified or who successfully completed an accredited program in psychiatry or child psychiatry.
 - o A licensed psychologist in his/her state of practice
 - o A licensed or certified social worker with master's degree and is listed on the National Association of Social Worker's Clinical Register
 - o A registered nurse (RN) certified as a psychiatric nurse or mental health clinical nurse specialist and has a master's degree in psychiatric/mental health
 - o An individual with a master's or a doctoral degree in marital and family therapy and at least two years of supervised clinical experience who is practicing as a marital and family therapist
 - o An individual with a master's or doctoral degree in counseling and at least two years of supervised clinical experience who is practicing as a professional counselor and licensed on the National Board for Certified Counselors (NBCC)

Follow-Up After Hospitalization for Mental Illness (FUH)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Cal Medi-Connect (CMC) Quality Performance Withhold

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 Codes

Refer to Mental Health Diagnosis Value Set and Mental Illness Value Set

CPT Codes

FUH Stand Alone Visits:	98960-98962, 99078, 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99384-99397, 99401-99404, 99408, 99411, 99412, 99483, 99510
FUH Visits Group 1:	90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876
FUH Visits Group 2:	99221-99223, 99231-99233, 99238, 99239, 99251-99255
TCM 14 Day:	99495
TCM 7 Day:	99496

CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205.

CPT Modifier codes for telehealth

95, GT, 02

HCPCS Codes

FUH Stand Alone Visits:	G0155, G0176, G0177, G0409, G0410, G0411, G0463, H0002, H0004, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, S0201, S9480, S9484, S9485, T1015
-------------------------	---

Exclusion(s)

Hospice, Nonacute Inpatient Stay

Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Q: Which members are included in the sample?

A: Adolescent and adult members (13 years and older) in 2021 with a new episode of alcohol or other drug (AOD) abuse or dependence who received the following:

- ☒ Members who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization, telehealth or medication treatment within 14 days of the diagnosis
- ☒ Members who initiated treatment and who had two or more additional AOD services or within 34 days of the initiation visit

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence from a claim/encounter data

1. New diagnosis of alcohol or other drug (AOD) abuse or dependence and date
2. Initiation of member treatment within 14 days of the AOD abuse or dependence diagnosis
 - a. Of these members who initiated treatment, evidence of two or more additional services (inpatient admissions, outpatient visits, telehealth, intensive outpatient encounters or partial hospitalizations with any AOD abuse or dependence diagnosis) within 34 days of the initiation treatment
 - i. Note that multiple engagement visits may occur on the same day, but they must be with different providers in order to count

Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Consider screening all members at office and/or telehealth visits using a substance abuse screening tool
- ☑ Perform SBIRT for members who answer positive for alcohol on the SHA or whom you suspect have an alcohol problem
- ☑ Once a member is identified with AOD abuse or dependence diagnosis, initiate brief intervention or refer for treatment within 14 days. Then complete at least two brief interventions within 34 days of diagnosis
- ☑ When referring members out to substance abuse providers, ensure an appointment is made within 14 days of diagnosis
- ☑ Exclude members from both Initiation of AOD Treatment and Engagement of AOD Treatment if the initiation of treatment event is an inpatient stay with a discharge date of November 27, 2021

Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET)

NCQA Accreditation – Medicaid
NCQA Accreditation – Medicare (CMC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

Refer to AOD Abuse and Dependence Value Set, AOD Alcohol Abuse and Dependence Value Set Value Set, Detoxification Value Set

CPT codes

IET Stand Alone Visits	98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99394-99397, 99401-99404, 99408, 99409, 99411, 99412, 99483, 99510
IET Visits Group 1	90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876
IET Visits Group 2	99221-99223, 99231-99233, 99238, 99239, 99251-99255

CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

CPT Modifier codes for telehealth

95, GT, 02

HCPCS codes

IET Stand Alone Visits	G0155, G0176, G0177, G0396, G0397, G0409-G0411, G0443, G0463, H0001, H0002, H0004, H0005, H0007, H0015, H0016, H0022, H0031, H0034-H0037, H0039, H0040, H0047, H2000, H2001, H2010-H2020, H2035, H2036, S0201, S9480, S9484, S9485, T1006, T1012, T1015
Detoxification	H0008-H0014

Exclusion(s)

AOD Abuse and Dependence, AOD Medication Treatment, Hospice

Immunizations for Adolescents (IMA)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P) (Combo 1)

NCQA Accreditation – Medicaid

Q: Which members are included in the sample?

A: Adolescents who had one dose of meningococcal conjugate vaccine (MCV), one tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) and 2 or 3 doses of the human papillomavirus (HPV) vaccines **by their 13th birthday.**

☒ Combo 1 - (Meningococcal, Tdap)

☒ Combo 2 - (Meningococcal, Tdap, HPV)

Note: The minimum interval for the two-dose HPV vaccination schedule is 150 days (5 months), with a 4-day grace period (146 days).

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: Must include any of the following:

- ☒ A note indicating the name of specific antigen and the date of the immunization
- ☒ A certificate of immunization that includes specific dates and types of immunizations administered
- ☒ Anaphylactic reaction to the vaccine or its components any time on or before the member's 13th birthday
- ☒ Anaphylactic reaction to the vaccine or its components with a date of service prior to October 1, 2013
- ☒ Encephalopathy with a vaccine adverse-effect anytime on or before the member's 13th birthday. (Tdap)

Meningococcal vaccine – given between member's 11th and 13th birthday

Tdap vaccine – given between member's 10th and 13th birthday

HPV vaccine – 2-doses (given 146 days apart) or 3 doses given between member's 9th and 13th birthday

Q: What type of medical record is acceptable?

A: One or more of the following:

- | | |
|--|---|
| <input checked="" type="checkbox"/> Certificate of immunization including specific dates and types of vaccines | <input checked="" type="checkbox"/> Print out of CAIR registry |
| <input checked="" type="checkbox"/> Immunization Record and health History Form | <input checked="" type="checkbox"/> Progress note/Office visit – with notations of vaccines given |
| <input checked="" type="checkbox"/> Health Maintenance Form/Report | <input checked="" type="checkbox"/> Notation of anaphylactic reaction to serum or vaccination |

Immunizations for Adolescents (IMA)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P) (Combo 1)

NCQA Accreditation – Medicaid

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Upload immunizations on to California Immunizations Registry (<http://cairweb.org>)
- ☑ Use the Childhood and Adolescent Wellness Flyers for Providers as a guideline of recommended health services for certain age groups (http://www.lacare.org/sites/default/files/LA1401_0815.pdf)
- ☑ Use every office visit (including sick visits) to provide immunizations and well-care visits
- ☑ Educate parents about the importance of timely vaccinations and share the immunization schedule
- ☑ Use EHR alerts to notify parents about needed immunizations
- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Ensure presence of all components in the medical record documentation of dates and types of immunizations, or contraindication for a specific vaccine

Immunizations for Adolescents (IMA)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P) (Combo 1)

NCQA Accreditation – Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

N/A

CPT codes

Meningococcal Vaccine	90734
Tdap Vaccine	90715
HPV Vaccine	90649-90651

HCPCS codes

N/A

Exclusion(s)

Anaphylactic Reaction Due To Serum, Anaphylactic Reaction Due To Vaccination, Encephalopathy Due To Vaccination, Hospice, Vaccine Causing Adverse Effect

Kidney Health Evaluation for Patients With Diabetes (KED)

Q: Which members are included in the sample?

A: Members 18–85 years of age with diabetes (type 1 and type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) and a urine albumin-creatinine ratio (uACR), in 2021.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires **claim/encounter data** submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence from a claim/encounter of members who received **both** of the following during 2021 on the same or different dates of service:

- At least one eGFR.
- At least one uACR identified by **both** a quantitative urine albumin test **and** a urine creatinine test **with** service dates four or less days apart. For example, if the service date for the quantitative urine albumin test was December 1 2021, then the urine creatinine test must have a service date on or between.

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Use of complete and accurate Value Set Codes.
- ☒ Timely submission of claims and encounter data
- ☒ Use of accurate Exclusion Codes
- ☒ Perform kidney health evaluation (eGFR) and (uACR) for members who were dispensed insulin or hypoglycemics/ antihyperglycemics on an ambulatory basis during 2021.

Kidney Health Evaluation for Patients With Diabetes (KED)

Q: How to improve score for this HEDIS measure?

Diabetes Medications

Description	Prescription
Alpha-glucosidase inhibitors	<ul style="list-style-type: none"> • Acarbose • Miglitol
Amylin analogs	<ul style="list-style-type: none"> • Pramlintide
Antidiabetic combinations	<ul style="list-style-type: none"> • Alogliptin-metformin • Alogliptin-pioglitazone • Canagliflozin-metformin • Dapagliflozin-metformin • Empagliflozin-linagliptin • Empagliflozin-metformin • Glimepiride-pioglitazone • Glipizide-metformin • Glyburide-metformin • Linagliptin-metformin • Metformin-pioglitazone • Metformin-repaglinide • Metformin-rosiglitazone • Metformin-saxagliptin • Metformin-sitagliptin
Insulin	<ul style="list-style-type: none"> • Insulin aspart • Insulin aspart-insulin aspart protamine • Insulin degludec • Insulin detemir • Insulin glargine • Insulin glulisine • Insulin isophane human • Insulin isophane-insulin regular • Insulin lispro • Insulin lispro-insulin lispro protamine • Insulin regular human • Insulin human inhaled
Meglitinides	<ul style="list-style-type: none"> • Nateglinide • Repaglinide
Glucagon-like peptide-1 (GLP1) agonists	<ul style="list-style-type: none"> • Dulaglutide • Liraglutide (excluding Saxenda®) • Albiglutide • Exenatide
Sodium glucose cotransporter 2 (SGLT2) inhibitor	<ul style="list-style-type: none"> • Canagliflozin • Empagliflozin • Dapagliflozin
Sulfonylureas	<ul style="list-style-type: none"> • Chlorpropamide • Glimepiride • Tolazamide • Glipizide • Glyburide • Tolbutamide
Thiazolidinediones	<ul style="list-style-type: none"> • Pioglitazone • Rosiglitazone
Dipeptidyl peptidase-4 (DDP-4) inhibitors	<ul style="list-style-type: none"> • Alogliptin • Linagliptin • Saxagliptin • Sitagliptin

EXCLUSIONS:

- Members with evidence of ESRD or dialysis any time during the member's history on or prior to December 31, 2021.
- Members receiving palliative care in 2021

Kidney Health Evaluation for Patients With Diabetes (KED)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

N/A

CPT codes

99201-99205, 99211-99215, 99241-99244

CPT Telephonic and Telehealth Codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

CPT Modifier Codes for Telehealth

95, GT, 02

HCPCS codes

G0402, G0438, G0439, G0463, T1015

Exclusion(s)

Chronic kidney disease stage 5, End stage renal disease, Dependence on renal dialysis

Use of Imaging Studies for Low Back Pain (LBP)

State Medicaid MPL (must achieve 50th percentile or greater)

NCQA Accreditation – Medicaid

Q: Which members are included in the sample?

A: Members 18-50 years of age with a primary diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence from claim/encounter data

- Imaging study with uncomplicated diagnosis of low back pain on the IESD or in the 28 days following the IESD.
Index Episode Start Date (IESD): The earliest date of service for an outpatient or ED encounter during the Intake Period (January 1, 2021 – December 3, 2021) with a principal diagnosis of low back pain.

Q: How to improve score for this HEDIS® measure?

- A:**
- ☑ Use of complete and accurate Value Set Codes
 - ☑ Timely submission of claim/encounter data
 - ☑ Proper coding or documentation of any of the following diagnoses for which imaging is clinically appropriate – *to assist in excluding members from the HEDIS® sample. See below for exclusion criteria.*

Exclusions: (Use designated Value Set for each)

Any of the following meet criteria:

- | | |
|--------------------------|------------------------------------|
| • Cancer | • HIV |
| • Recent Trauma | • Spinal infection |
| • Intravenous drug abuse | • Major organ transplant |
| • Neurologic impairment | • Prolonged use of corticosteroids |

Use of Imaging Studies for Low Back Pain (LBP)

State Medicaid MPL (must achieve 50th percentile or greater)

NCQA Accreditation – Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

Refer to Uncomplicated Low Back Pain Value Set

CPT codes

Imaging Study	72020, 72052, 72100, 72110, 72114, 72120, 72131-72133, 72141, 72142, 72146-72149, 72156, 72158, 72200, 72202, 72220
Observation	99217-99220
Osteopathic and Chiropractic Manipulative Treatment	98925-98929, 98940-98942
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456

CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

CPT Modifier codes for telehealth

95, GT, 02

HCPCS codes

Outpatient	G0402, G0438, G0439, G0463, T1015
------------	-----------------------------------

Exclusion(s)

History of Malignant Neoplasm, HIV, Hospice, Intravenous Drug Abuse, Major Organ Transplant, Malignant Neoplasms, Neurologic Impairment, Other Malignant Neoplasm of Skin, Other Neoplasms, Prolonged Use of Corticosteroids, Recent Trauma, Spinal Infection

Osteoporosis Management in Women Who Had a Fracture (OMW)

NCQA Accreditation – Medicare (CMC)

Q: Which members are included in the sample?

A: Women 67-85 years of age who suffered a fracture (7/1/2020 - 6/30/2021), and who had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: None. This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence of claim/encounter data:

- ☒ Bone Mineral Density (BMD) test, in any setting, on the Index Episode Start Date (IESD) or in the 180-day (6 month) period after the IESD
- ☒ If IESD was an inpatient, a BMD test during inpatient stay
- ☒ Osteoporosis therapy on the IESD or in the 180-day (6 month) period after IESD
- ☒ If the IESD was an inpatient, long-acting osteoporosis therapy during the inpatient stay
- ☒ A dispensed prescription to treat osteoporosis on the IESD or in the 180-day (6 month) period after IESD
- ☒ A dispensed prescription to treat osteoporosis
- ☒ Fracture
- ☒ Visit type

Osteoporosis Medications

Description	Prescription	
Biphosphonates	<ul style="list-style-type: none">• Alendronate• Alendronate-cholecalciferol• Ibandronate	<ul style="list-style-type: none">• Risedronate• Zoledronic Acid
Other agents	<ul style="list-style-type: none">• Abaloparatide• Romosozumab• Denosumab	<ul style="list-style-type: none">• Raloxifene• Teriparatide

Osteoporosis Management in Women Who Had a Fracture (OMW)

NCQA Accreditation – Medicare (CMC)

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Ensure presence of all components in the medical record documentation
- ☑ ***Required Exclusions:***
 - Members who had a BMD test during the 730 days (24 months) prior to IESD*
 - Members who had a claim/encounter for osteoporosis therapy during the 365 days (12 months) prior to IESD*
 - Member who received a dispensed prescription or had an active prescription to treat osteoporosis during the 365 days (12 months) prior to IESD*
 - Members who received palliative care during the intake period through the end of 2021.
 - Members who are enrolled in an Institutional SNP (I-SNP) any time in 2021.
 - Members living long-term in an institution any time in 2021.

Note: *Fractures of finger, toe, face and skull are not included.*

*IESD: Index Episode Start Date [The earliest date of service for any encounter during the Intake Period (7/1/2020 – 6/30/2021) with a diagnosis of fracture]

Osteoporosis Management in Women Who Had a Fracture (OMW)

NCQA Accreditation – Medicare (CMC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

Refer to Fractures Value Set

CPT codes

Bone Mineral Density Tests	76977, 77078, 77080, 77081, 77082, 77085, 77086
Fractures	Refer to Fractures Value Set
Observation	99217-99220
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483

CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

CPT Modifier codes for telehealth

95, GT, 02

HCPCS codes

Fractures	S2360
Long-Acting Osteoporosis Medications	J0897, J1740, J3489

Osteoporosis Management in Women Who Had a Fracture (OMW)

NCQA Accreditation – Medicare (CMC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

HCPCS codes	
Osteoporosis Medications	J0630, J0897, J1740, J3110, J3489,
Outpatient	G0402, G0438, G0439, G0463, T1015

Exclusion(s)
Advanced Illness, Bone Mineral Density Tests, Frailty, Hospice, Osteoporosis Medications, Palliative Care Assessment Value Set, Palliative Care Encounter Value Set, Palliative Care Intervention Value Set

Osteoporosis Screening in Older Women (OSW)

Q: Which members are included in the sample?

A: Women 65–75 years of age who received osteoporosis screening in 2021.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires **claim/encounter data** submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence from a claim/encounter with a date of service for one or more osteoporosis screening tests on or between the member's 65th birthday and December 31, 2021.

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Use of complete and accurate Value Set Codes.
- ☒ Timely submission of claims and encounter data
- ☒ Use of accurate Exclusion Codes

Exclusions:

- Members who had a claim/encounter for osteoporosis therapy any time in the member's history through December 31, 2021.
- Members who had a dispensed prescription to treat osteoporosis anytime on or between January 1, 2018 through December 31, 2021.
- Members receiving palliative care in 2021.

Osteoporosis Medications

Description	Prescription
Biphosphonates	<ul style="list-style-type: none">• Alendronate• Alendronate-cholecaliferol• Ibandronate• Risedronate• Zoledronic Acid
Other agents	<ul style="list-style-type: none">• Abaloparatide• Denosumab• Raloxifene• Romosozumab• Teriparatide

Osteoporosis Screening in Older Women (OSW)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

N/A

CPT codes

76977, 77078, 77080, 77081, 77085

CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

CPT Modifier codes for telehealth

95, GT, 02

HCPCS codes

N/A

Exclusion(s)

Terminal cancer, end-of-life care planning, Encounter for Palliative care, Treatment due to osteoporosis or bone loss. Hospice setting, Comprehensive management and care coordination for advanced illness, Direct skilled nursing services of a registered nurse.

Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)

NCQA Accreditation – Medicare (CMC)

Q: Which members are included in the sample?

A: Members 18 years of age and older who were hospitalized and discharged from July 1, 2020 to June 30, 2021 with a diagnosis of AMI and who received persistent beta-blocker treatment for six months after discharge.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence from claim/encounter data of an acute inpatient discharge with any diagnosis of AMI from July 1, 2020 – June 30, 2021 and at least 135 days of treatment with beta-blockers during the 180-day measurement interval.

Beta-Blocker Medications

Description	Prescription
Noncardioselective beta-blockers	<ul style="list-style-type: none">• Carvedilol• Labetalol• Nadolol• Pindolol• Propranolol• Timolol• Sotalol
Cardioselective beta-blockers	<ul style="list-style-type: none">• Acebutolol• Atenolol• Betaxolol• Bisoprolol• Metoprolol• Nebivolol
Antihypertensive Combinations	<ul style="list-style-type: none">• Atenolol-chlorthalidone• Bendroflumethiazide-nadolol• Bisoprolol-hydrochlorothiazide• Hydrochlorothiazide-metoprolol• Hydrochlorothiazide-propranolol

Q: How to improve score for this HEDIS® measure?

A: Use of complete and accurate Value Set Codes.

Timely submission of claim/encounter data.

Exclude members identified as having intolerance or allergy to beta blocker therapy. Any of the following meet criteria:

- ☒ Asthma
- ☒ COPD
- ☒ Obstructive chronic bronchitis
- ☒ Chronic respiratory conditions due to fumes and vapors
- ☒ Hypotension, heart block >1 degree or sinus bradycardia
- ☒ A medication dispensing event indicative of a history or asthma
- ☒ Intolerance or allergy to beta-blocker therapy

Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)

NCQA Accreditation – Medicare (CMC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

AMI	I21.01, I21.02, I21.09, I21.11, I21.19, I21.21, I21.29, I21.3, I21.4
-----	--

UBREV codes

Refer to Inpatient Stay Value Set

Exclusion(s)

Advanced Illness, Adverse Effects of Beta-Adrenoreceptor Antagonists, Asthma, Beta-Blockers Contraindications, Chronic Respiratory Conditions Due to Fumes/Vapors, COPD, Frailty, Obstructive Chronic Bronchitis
--

Pharmacotherapy Management of COPD Exacerbation (PCE)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Q: Which members are included in the sample?

A: Members 40 years of age and older with COPD exacerbations who had an acute inpatient discharge or ED visit on or between January 1, 2021 – November 30, 2021, and who were dispensed a systemic corticosteroid within 14 days of the event and/or a bronchodilator within 30 days of the event.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence from claim/encounter data

1. Dispensed prescription for systemic corticosteroid on or 14 days after the Episode Date.

Systemic Corticosteroid Medications

Description	Prescription		
Glucocorticoids	• Cortisone-acetate	• Hydrocortisone	• Prednisolone
	• Dexamethsone	• Methylprednisolone	• Prednisone

Pharmacotherapy Management of COPD Exacerbation (PCE)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Q: What type of document is acceptable?

A:

2. Dispensed prescription for a bronchodilator on or 30 days after the Episode Date.

Bronchodilator Medications

Description	Prescription		
Anticholinergic agents	<ul style="list-style-type: none">• Acclidinium-Bromide• Tiotropium	<ul style="list-style-type: none">• Ipratropium• Umeclidinium	
Beta 2-agonists	<ul style="list-style-type: none">• Albuterol• Arformoterol• Formoterol	<ul style="list-style-type: none">• Indacaterol• Levalbuterol	<ul style="list-style-type: none">• Metaproterenol• Salmeterol
Bronchodilator combinations	<ul style="list-style-type: none">• Albuterol-ipratropium• Budesonide-formoterol• Dyphylline-guaifensin• Fluticasone-vilanterol• Fluticasone furoate-umeclidinium-vilanterol	<ul style="list-style-type: none">• Fluticasone-vilanterol• Formoterol-acclidinium• Formoterol-glycopyrrolate• Formoterol-mometasone	<ul style="list-style-type: none">• Indacaterol-glycopyrrolate• Olodaterol hydrochloride• Olodaterol-tiotropium• Umeclidinium-vilanterol

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data

Pharmacotherapy Management of COPD Exacerbation (PCE)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes	
Chronic Bronchitis	J41.0, J41.1, J41.8, J42
Emphysema	J43.0, J43.1, J43.2, J43.8, J43.9
COPD	J44.0, J44.1, J44.9

CPT codes	
ED	99281-99285

HCPCS codes	
N/A	

Exclusion(s)	
Inpatient Stay, Nonacute Inpatient Stay	

Plan All-Cause Readmissions (PCR) Star Measure

NCQA Accreditation - Medicare (CMC)

Cal Medi-Connect (CMC) Quality Performance Withhold

Q: Which members are included in the sample?

A: For members 18 years of age and older, the number of acute inpatient and observation stays in 2021 that were followed by an unplanned acute readmission for any diagnosis within 30 days and the predicted probability of an acute readmission.

- Count of Index Hospital Stays (IHS) (denominator)
- Count of Observed 30-Day Readmissions (numerator)
- Count of Expected 30-Day Readmissions

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence from claim/encounter data of at least one acute readmission for any diagnosis within 30 days of the Index Discharge Date (on or between January 1 and December 1, 2021).

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Review discharges and verify that they are for acute IP stays. Some maybe sub-acute, transitional care, rehab, etc.
- ☑ Schedule a follow-up once member has been discharged from the hospital to assess how the member doing to avoid possible readmission
- ☑ Capture all diagnoses as this is a case mix adjusted rate. *The sicker the member, the higher probability of a readmission*

Plan All-Cause Readmissions (PCR) Star Measure

NCQA Accreditation - Medicare (CMC)

Cal Medi-Connect (CMC) Quality Performance Withhold

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

None

UBREV codes

Refer to Inpatient Stay Value Set

CPT codes

None

Exclusion(s)

Acute Condition, Bone Marrow Transplant, Chemotherapy, Introduction of Autologous Pancreatic Cells, Kidney Transplant, Nonacute Inpatient Stay, Organ Transplant Other Than Kidney, Perinatal Conditions, Potentially Planned Procedures, Pregnancy, Rehabilitation

Proportion of Days Covered (PDC)

Q: Which members are included in the sample?

A: Members 18 years and older who met the Proportion of Days Covered (PDC) threshold of 80 percent during 2021 for the following rates:

- Renin Angiotensin System (RAS) Antagonists
- Diabetes All Class
- Statins

Q: What codes are used?

A: N/A

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence from a claim/encounter data

1. *Renin Angiotensin System (RAS) Antagonists.* Members who filled at least two prescriptions for a RAS Antagonist on different dates of service during the treatment period.

Table PDC-RASA-A: Renin Angiotensin System (RAS) Antagonists

Direct Renin Inhibitor Medications and Combinations	<ul style="list-style-type: none"> • aliskiren (+/- amlodipine, hydrochlorothiazide) 	
ARB Medications and Combinations	<ul style="list-style-type: none"> • azilsartan (+/- chlorthalidone) • candesartan (+/- hydrochlorothiazide) • eprosartan (+/- hydrochlorothiazide) • irbesartan (+/- hydrochlorothiazide) • losartan (+/- hydrochlorothiazide) 	<ul style="list-style-type: none"> • olmesartan (+/- amlodipine, hydrochlorothiazide) • telmisartan (+/- amlodipine, hydrochlorothiazide) • valsartan (+/- amlodipine, hydrochlorothiazide nebulolol)
ACE Inhibitor Medications and Combination Products	<ul style="list-style-type: none"> • benazepril (+/- amlodipine, hydrochlorothiazide) • captopril (+/- hydrochlorothiazide) • enalapril (+/- hydrochlorothiazide) • fosinopril (+/- hydrochlorothiazide) • lisinopril (+/- hydrochlorothiazide) 	<ul style="list-style-type: none"> • moexipril (+/- hydrochlorothiazide) • perindopril (+/- amlodipine) • quinapril (+/- hydrochlorothiazide) • ramipril •trandolapril (+/- verapamil)

Proportion of Days Covered (PDC)

Q: What type of documentation is acceptable?

EXCLUSION:

Table PDC-RASA-B

ARB/Neprilysin Inhibitor Combination Medication

- Sacubitril/Valsartan

2. *Diabetes All Class*. Members who filled at least two prescriptions for any of the diabetes medications listed below on different dates of service during the treatment period who met the PDC threshold in 2020.

Table PDC-DR-A: Biguanides

Biguanide Medications and Combinations

- metformin (+/- alogliptin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, glipizide, glyburide, linagliptin, pioglitazone, repaglinide, rosiglitazone, saxagliptin, sitagliptin)

Table PDC-DR-B: Sulfonylureas

Sulfonylurea Medications and Combinations

- chlorpropamide
- glimepiride (+/- pioglitazone)
- glipizide (+/- metformin)
- glyburide (+/- metformin)
- tolazamide
- tolbutamide

Table PDC-DR-C: Thiazolidinediones

Thiazolidinedione Medications and Combinations

- pioglitazone (+/- alogliptin, glimepiride, metformin)
- rosiglitazone (+/- metformin)

Table PDC-DR-D: DPP-4 Inhibitors

DPP-4 Medications and Combinations

- alogliptin (+/- metformin, pioglitazone)
- linagliptin (+/- empagliflozin, metformin)
- saxagliptin (+/- metformin, dapagliflozin)
- sitagliptin (+/- metformin, ertugliflozin)

Table PDC-DR-E: Incretin Mimetics

DPP-4 Medications and Combinations

- alogliptin (+/- metformin, pioglitazone)
- linagliptin (+/- empagliflozin, metformin)
- saxagliptin (+/- metformin, dapagliflozin)
- sitagliptin (+/- metformin, ertugliflozin)

Table PDC-DR-F: Meglitinides

Meglitinides and Combinations

- repaglinide (+/- metformin)

Table PDC-DR-G: Sodium Glucose Co-Transporter2 (SGLT2) Inhibitors

SGLT2 Inhibitors and Combinations

- canagliflozin (+/- metformin)
- dapagliflozin (+/- metformin, saxagliptin)
- empagliflozin (+/- metformin, linagliptin)
- ertugliflozin (+/- sitagliptin, metformin)

Proportion of Days Covered (PDC)

Q: What type of documentation is acceptable? *continued*

EXCLUSION:

Table PDC-H: Insulin Exclusion

Insulins		
<ul style="list-style-type: none">insulin aspart (+/-insulin aspart protamine)insulin degludec (+/- liraglutide)insulin detemir	<ul style="list-style-type: none">insulin glargine (+/- lixisenatide)insulin glulisineinsulin isophane (+/- regular insulin)	<ul style="list-style-type: none">insulin lispro (+/- insulin lispro protamine)insulin regular (including inhalation powder)

3. *Statins*. Members who filled at least two prescriptions for a statin or statin combination on different dates of service during the treatment period.

Table PDC-STA-A: Statins

Statin Medications		
<ul style="list-style-type: none">atorvastatin (+/- amlodipine, ezetimibe)fluvastatin	<ul style="list-style-type: none">lovastatin (+/- niacin)pitavastatin	<ul style="list-style-type: none">pravastatinrosuvastatinsimvastatin (+/-ezetimibe, niacin)

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Timely submission of claim/encounter data

Prenatal and Postpartum Care (PPC)

State Medicaid Auto-Assignment (Timeliness of Prenatal Care)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

Q: Which members are included in the sample?

A:

- ☑ Women who delivered (EDD) between October 8, 2020 - October 7, 2021, *and*
- ☑ Had a prenatal care visits in the first trimester, on or before the enrollment start date or within 42 days of enrollment in the organization, *and*
- ☑ Had a postpartum visit on or between 7 and 84 days after delivery

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is acceptable?

Prenatal Care Visit (First Trimester, on date of enrollment, or within 42 days of enrollment)

- I. Documentation indicating the woman is pregnant or references to the pregnancy; for example:
 - a. Documentation in a standardized prenatal flow sheet, or
 - b. Documentation of LMP, EDD or gestational age, or
– A positive pregnancy test result, or
 - c. Documentation of gravidity and parity, or
 - d. Documentation of complete obstetrical history, or
 - e. Documentation of prenatal risk assessment and counseling/education.
- ii. A basic physical obstetrical examination that includes auscultation for fetal heart tone, or pelvic exam with obstetric observations, or measurement of fundus height (a standardized prenatal flow sheet may be used).
- iii. Evidence that a prenatal care procedure was performed, such as:
 - a. Screening test in the form of an obstetric panel (must include all of the following: hematocrit, differential WBC count, platelet count, hepatitis B surface antigen, rubella antibody, syphilis test, RBC antibody screen, Rh and ABO blood typing), or
 - b. TORCH antibody panel alone, or
 - c. A rubella antibody test/titer with an Rh incompatibility (ABO/Rh) blood typing, or
 - d. Ultrasound of a pregnant uterus.

Post-partum Visit (7 and 84 days after delivery)

Progress note with documentation of:

- i. Pelvic exam
- ii. Evaluation of weight, BP, breasts and abdomen.
– Notation of “breastfeeding” is acceptable for the “evaluation of breasts” component.
- iii. Notation of postpartum care, including, but not limited to: – Notation of “postpartum care,” “PP care,” “PP check,” “6-week check.”
– A preprinted “Postpartum Care” form in which information was documented during the visit.
- iv. Perineal or cesarean incision/wound check.
- v. Screening for depression, anxiety, tobacco use, substance use disorder, or preexisting mental health disorders.
- vi. Glucose screening for women with gestational diabetes.
- vii. Documentation of any of the following topics:
 - a. Infant care or breastfeeding.
 - b. Resumption of intercourse, birth spacing or family planning.
 - c. Sleep/fatigue.
 - d. Resumption of physical activity.
 - e. Attainment of healthy weight.

Prenatal and Postpartum Care (PPC)

State Medicaid Auto-Assignment (Timeliness of Prenatal Care)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claims/encounter data
- ☑ Services provided during a telephone visit, e-visit or virtual check-in meet criteria for both Timeliness of Prenatal Care and Postpartum Care
- ☑ Ensure presence of all components in the medical record documentation
- ☑ May use EDD to identify the first trimester for Timeliness of Prenatal Care and use the date of delivery for the Postpartum rate
- ☑ Documentation of deliveries **NOT** resulting in a Live Birth – *proper coding or documentation will assist in excluding members from the HEDIS® sample*

Prenatal and Postpartum Care (PPC)

State Medicaid Auto-Assignment (Timeliness of Prenatal Care)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for -Performance (P4P)

NCQA Accreditation – Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 Pregnancy codes

Refer to Pregnancy Diagnosis Value Set

CPT Delivery codes

59400, 59409, 59410, 59510, 59514, 59515, 59610, 59612, 59614, 59618, 59620, 59622

PRENATAL CARE

CPT Prenatal Ultrasound codes

76801, 76805, 76811, 76813, 76815-76821, 76825-76828

Prenatal and Postpartum Care (PPC)

State Medicaid Auto-Assignment (Timeliness of Prenatal Care)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

CPT Stand Alone Prenatal Visit code

99500

CPT Prenatal Visit codes

99201-99205, 99211-99215, 99241-99245, 99483

CPT II Stand Alone Prenatal Visit codes

0500F, 0501F, 0502F

CPT Prenatal Bundled Service codes

59400, 59425, 59426, 59510, 59610, 59618

CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

CPT Modifier codes for telehealth

95, GT, 02

HCPCS Prenatal codes

Prenatal Visits

G0463, T1015

Stand Alone Prenatal Visits

H1000-H1004

Prenatal Bundled Services

H1005

POSTPARTUM CARE

ICD-10 Postpartum Visit codes

Z01.411, Z01.419, Z01.42, Z30.430, Z39.1, Z39.2

Prenatal and Postpartum Care (PPC)

State Medicaid Auto-Assignment (Timeliness of Prenatal Care)

State Medicaid MPL (must achieve 50th percentile or greater)

Pay-for-Performance (P4P)

NCQA Accreditation – Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

CPT Postpartum Visit codes

57170, 58300, 59430, 99501

CPT II Postpartum Visit codes

0503F

CPT Postpartum Bundled Service codes

59400, 59410, 59510, 59515, 59610, 59614, 59618, 59622

HCPCS Postpartum codes

Postpartum Visits

G0101

Cervical Cytology

G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091

Exclusion(s)

Non-Live Births

Statin Therapy for Patients With Cardiovascular Disease (SPC)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Q: Which members are included in the SAMPLE?

A: Males 21 – 75 years of age and females 40 – 75 years of age who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and were dispensed at least one high or moderate-intensity statin medication in 2021 and remained on it for at least 80% of the treatment period.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence from claim/encounter data:

1. *Received Statin Therapy.* Dispensed prescription for a high or moderate-intensity statin medication in 2020

High- and Moderate-Intensity Statin Medications:

Description	Prescription	Medication Lists
High-intensity statin therapy	• Atorvastatin 40-80 mg	• Atorvastatin High Intensity Medications List
	• Amlodipine-atorvastatin 40-80 mg	• Amlodipine Atorvastatin High Intensity Medications List
	• Rosuvastatin 20-40 mg	• Rosuvastatin High Intensity Medications List
	• Simvastatin 80 mg	• Simvastatin High Intensity Medications List
	• Ezetimibe-simvastatin 80 mg	• Ezetimibe Simvastatin High Intensity Medications List

Statin Therapy for Patients With Cardiovascular Disease (SPC)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Description	Prescription	Medication Lists
Moderate-intensity statin therapy	• Atorvastatin 10-20 mg	• Atorvastatin Moderate Intensity Medications List
	• Amlodipine-atorvastatin 10-20 mg	• Amlodipine Atorvastatin Moderate Intensity Medications List
	• Rosuvastatin 5-10 mg	• Rosuvastatin Moderate Intensity Medications List
	• Simvastatin 20-40 mg	• Simvastatin Moderate Intensity Medications List
	• Ezetimibe-simvastatin 20-40 mg	• Ezetimibe Simvastatin Moderate Intensity Medications List
	• Pravastatin 40-80 mg	• Pravastatin Moderate Intensity Medications List
	• Lovastatin 40 mg	• Lovastatin Moderate Intensity Medications List
	• Fluvastatin 40-80 mg	• Fluvastatin Moderate Intensity Medications List
	• Pitavastatin 2–4 mg	• Pitavastatin Moderate Intensity Medications List

EXCLUSIONS:

Estrogen Agonist Medications:

Description	Prescription
Estrogen agonists	• Clomiphene

Dementia Medications

Description	Prescription
Cholinesterase inhibitors	• Donepezil • Galantamine • Rivastigmine
Miscellaneous central nervous system agents	• Memantine
Dementia combinations	• Donepezil-memantine

Statin Therapy for Patients With Cardiovascular Disease (SPC)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Q: What type of documentation is acceptable?

2. *Statin Adherence 80%*. Proportion of days covered (PDC) by prescription medication for at least 80% of the treatment period based on pharmacy claims from earliest dispensing event in 2021.

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Use of complete and accurate Value Set Codes
- ☒ Timely submission of claim/encounter data
- ☒ Services provided during a telephone visit, e-visit or virtual check-in meet criteria for advanced illness exclusion.

Statin Therapy for Patients With Cardiovascular Disease (SPC)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

Refer to IVD Value Set and MI Value Set

CPT codes

Acute Inpatient	99221 – 99223, 99231 – 99233, 99238, 99239, 99251-99255, 99291
CABG	33510 – 33514, 33516 – 33519, 33521 – 33523, 33533 – 33536
Other Revascularization	37220, 37221, 37224 – 37231
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483
PCI	92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980, 92982

CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

CPT Modifier codes for telehealth

95, GT, 02

HCPCS codes

CABG	S2205 – S2209
PCI	C9600, C9602, C9604, C9606, C9607

Exclusion(s)

Advanced Illness, Cirrhosis, ESRD, Frailty, IVE, Muscular Pain and Disease, Pregnancy

Statin Therapy for Patients With Diabetes (SPD)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Q: Which members are included in the SAMPLE?

A: Members 40 – 75 years of age with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) and were dispensed at least one statin medication of any intensity in 2021 and remained on it for at least 80% of the treatment period.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence from claim/encounter data

1. *Received Statin Therapy.* Dispensed prescription for a high, moderate, or low-intensity statin medication in 2021

High- and Moderate-Intensity Statin Medications:

Description	Prescription	Medication Lists
High-intensity statin therapy	• Atorvastatin 40-80 mg	• Atorvastatin High Intensity Medications List
	• Amlodipine-atorvastatin 40-80 mg	• Amlodipine Atorvastatin High Intensity Medications List
	• Rosuvastatin 20-40 mg	• Rosuvastatin High Intensity Medications List
	• Simvastatin 80 mg	• Simvastatin High Intensity Medications List
	• Ezetimibe-simvastatin 80 mg	• Ezetimibe Simvastatin High Intensity Medications List

Statin Therapy for Patients With Diabetes (SPD)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Description	Prescription	Medication Lists
Moderate-intensity statin therapy	• Atorvastatin 10-20 mg	• Atorvastatin Moderate Intensity Medications List
	• Amlodipine-atorvastatin 10-20 mg	• Amlodipine Atorvastatin Moderate Intensity Medications List
	• Rosuvastatin 5-10 mg	• Rosuvastatin Moderate Intensity Medications List
	• Simvastatin 20-40 mg	• Simvastatin Moderate Intensity Medications List
	• Ezetimibe-simvastatin 20-40 mg	• Ezetimibe Simvastatin Moderate Intensity Medications List
	• Pravastatin 40-80 mg	• Pravastatin Moderate Intensity Medications List
	• Lovastatin 40 mg	• Lovastatin Moderate Intensity Medications List
	• Fluvastatin 40-80 mg	• Fluvastatin Moderate Intensity Medications List
	• Pitavastatin 1–4 mg	• Pitavastatin Moderate Intensity Medications List
Low-intensity statin therapy	• Ezetimibe-simvastatin 10 mg	• Ezetimibe Simvastatin Low Intensity Medications List
	• Fluvastatin 20 mg	• Fluvastatin Low Intensity Medications List
	• Lovastatin 10-20 mg	• Lovastatin Low Intensity Medications List
	• Pitavastatin 1 mg	• Pitavastatin Low Intensity Medications List
	• Pravastatin 10–20 mg	• Pravastatin Low Intensity Medications List
	• Simvastatin 5-10 mg	• Simvastatin Low Intensity Medications List

Statin Therapy for Patients With Diabetes (SPD)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

Q: What type of document is acceptable?

EXCLUSIONS:

Estrogen Agonist Medications:

Description	Prescription
Estrogen agonists	<ul style="list-style-type: none">• Clomiphene

Dementia Medications

Description	Prescription
Cholinesterase inhibitors	<ul style="list-style-type: none">• Donepezil• Galantamine• Rivastigmine
Miscellaneous central nervous system agents	<ul style="list-style-type: none">• Memantine
Dementia combinations	<ul style="list-style-type: none">• Donepezil-memantine

2. *Statin Adherence 80%*. Proportion of days covered (PDC) by prescription medication for at least 80% of the treatment period based on pharmacy claims from earliest dispensing event in 2021.

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Use of complete and accurate Value Set Codes
- ☒ Timely submission of claim/encounter data
- ☒ Services provided during a telephone visit, e-visit or virtual check-in meet criteria for advanced illness exclusion.

Statin Therapy for Patients With Diabetes (SPD)

NCQA Accreditation – Medicaid

NCQA Accreditation – Medicare (CMC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

Refer to Diabetes Value Set

CPT codes

Acute Inpatient	99221 – 99223, 99231 – 99233, 99238, 99239, 99251 – 99255, 99291
Outpatient	99201 – 99205, 99211 – 99215, 99241 – 99245, 99341 – 99345, 99347 – 99350, 99381 – 99387, 99391 – 99397, 99401 – 99404, 99411, 99412, 99429, 99455, 99456, 99483
Nonacute Inpatient	99304 – 99310, 99315, 99316, 99318, 99324 – 99328, 99334 – 99337

CPT Telephonic and Telehealth codes

99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205

CPT Modifier codes for telehealth

95, GT, 02

Exclusion(s)

Advanced Illness, CABG, Cirrhosis, Diabetes, Diabetes Exclusions, ESRD, Frailty, IVD, IVE, MI, Muscular Pain and Disease, Other Revascularization, PCI, Pregnancy

Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)

Q: Which members are included in the SAMPLE?

A: Members 40 years of age and older with a new diagnosis of COPD or newly active COPD, who received appropriate spirometry testing to confirm the diagnosis.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: What type of document is acceptable?

A: Evidence from claim/encounter data:

- At least one spirometry test confirming diagnosis of Chronic Obstructive Pulmonary Disease (COPD) during the 730 days (2 years) prior to the IESD through 180 days (6 months) after the IESD.

Index Episode Start Date (IESD): The earliest date of service for an eligible visit (outpatient, ED, or acute inpatient) during the Intake Period (July 1, 2020 - June 30, 2021) with any diagnosis of COPD.

Q: How to improve score for this HEDIS® measure?

- A:**
- ☒ Use of complete and accurate Value Set Codes
 - ☒ Timely submission of claim/encounter data
 - ☒ Services provided during a telephone visit, e-visit or virtual check-in meet criteria for eligible population.

Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes	
Chronic Bronchitis	J41.0, J41.1, J41.8, J42
Emphysema	J43.0, J43.1, J43.2, J43.8, J43.9
COPD	J44.0, J44.1, J44.9
CPT codes	
Spirometry	94010, 94014-94016, 94060, 94070, 94375, 94620
ED	99281-99285
Observation	99217-99220
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483
CPT Telephonic and Telehealth codes	
99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205	
CPT Modifier codes for telehealth	
95, GT, 02	
HCPCS codes	
Outpatient	G0402, G0438, G0439, G0463, T1015
Exclusion(s)	
Chronic Bronchitis, COPD, Emphysema, Inpatient Stay, Nonacute Inpatient Stay, Telehealth Modifier, Telehealth POS	

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

NCQA Accreditation – Medicaid

Q: Which members are included in the sample?

A: Adults 18- 64 years of age with schizophrenia, schizoaffective disorder or bipolar disorder, who were dispensed an antipsychotic medication and had a glucose test or an HbA1c test in 2021.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes and pharmacy data.

Q: What type of document is acceptable?

A: Evidence from claim/encounter or lab data:

- Glucose test in 2021
- HbA1c test in 2021

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Use of complete and accurate Value Set Codes
- ☒ Timely submission of claim/encounter data
- ☒ Services provided during a telephone visit, e-visit or virtual check-in meet criteria for eligible population.

Q: Which members are excluded?

A:

- Members with diabetes identified by claim/encounter and pharmacy data in 2020 or 2021
- Members who were dispensed insulin or oral hypoglycemics/antihyperglycemics in 2020 or 2021
- Members who had no antipsychotic medications dispensed in 2021

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

NCQA Accreditation – Medicaid

Antipsychotic Medications

Diabetes Medications

Description	Prescription
Alpha-glucosidase inhibitors	<ul style="list-style-type: none"> Acarbose Miglitol
Amylin analogs	<ul style="list-style-type: none"> Pramlintide
Antidiabetic combinations	<ul style="list-style-type: none"> Alogliptin-metformin Alogliptin-pioglitazone Canagliflozin-metformin Dapagliflozin-metformin Empagliflozin-linagliptin Empagliflozin-metformin Glimepiride-pioglitazone Glipizide-metformin Glyburide-metformin Linagliptin-metformin Metformin-pioglitazone Metformin-repaglinide Metformin-rosiglitazone Metformin-saxagliptin Metformin-sitagliptin
Insulin	<ul style="list-style-type: none"> Insulin aspart Insulin aspart-insulin aspart protamine Insulin degludec Insulin detemir Insulin glargine Insulin glulisine Insulin isophane human Insulin isophane-insulin regular Insulin lispro Insulin lispro-insulin lispro protamine Insulin regular human Insulin human inhaled
Meglitinides	<ul style="list-style-type: none"> Nateglinide Repaglinide
Glucagon-like peptide-1 (GLP1) agonists	<ul style="list-style-type: none"> Dulaglutide Liraglutide (excluding Saxenda®) Albiglutide Exenatide
Sodium glucose cotransporter 2 (SGLT2) inhibitor	<ul style="list-style-type: none"> Canagliflozin Empagliflozin Dapagliflozin
Sulfonylureas	<ul style="list-style-type: none"> Chlorpropamide Glimepiride Tolazamide Glipizide Glyburide Tolbutamide
Thiazolidinediones	<ul style="list-style-type: none"> Pioglitazone Rosiglitazone
Dipeptidyl peptidase-4 (DDP-4) inhibitors	<ul style="list-style-type: none"> Alogliptin Linagliptin Saxagliptin Sitagliptin

SSD Antipsychotic Medications

Description	Prescription
Miscellaneous antipsychotic agents	<ul style="list-style-type: none"> Aripiprazole Asenapine Brexipiprazole Cariprazine Clozapine Haloperidol Iloperidone Loxapine Lurasidone Molindone Olanzapine Paliperidone Quetiapine Risperidone Ziprasidone
Phenothiazine antipsychotics	<ul style="list-style-type: none"> Chlorpromazine Fluphenazine Perphenazine Prochlorperazine Thioridazine Trifluoperazine
Psychotherapeutic combinations	<ul style="list-style-type: none"> Amitriptyline-perphenazine
Thioxanthenes	<ul style="list-style-type: none"> Thiothixene
Long-acting injections	<ul style="list-style-type: none"> Aripiprazole Fluphenazine decanoate Haloperidol decanoate Olanzapine Paliperidone palmitate Risperidone

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

NCQA Accreditation – Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes

ICD-10 codes

F20.9 Schizophrenia, unspecified

F31.9 Bipolar disorder, unspecified

F30.9 Manic episode, unspecified

CPT codes

Non Acute Inpatient	99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337
Acute Inpatient	99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291

HCPCS codes

Annual wellness visit; includes a personalized prevention plan of service, initial visit	G0438
Behavioral health counseling and therapy, per 15 minutes	H0004
Mental health assessment, by non-physician	H0031
Comprehensive medication services, per 15 minutes	H2010
Skills training and development, per 15 minutes	H2014
Therapeutic behavioral services, per 15 minutes	H2019

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

NCQA Accreditation – Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

Exclusion(s)

Diabetes, Long-Acting Injections, SSD Antipsychotic Medications List

Transitions of Care (TRC)

Q: Which members are included in the sample?

A: Member 18 years and older who were discharged from acute or in acute setting from January 1, 2021 and December 1, 2021:

- Notification of Inpatient Admission
- Receipt of Discharge Information
- Patient Engagement After Inpatient Discharge
- Medication Reconciliation Post-Discharge

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: Documentation in the medical record must include evidence of the following:

- Documentation of receipt of notification of inpatient admission on the day of admission through 2 days after the admission (3 total days).
- Documentation of receipt of discharge information on the day of discharge through 2 days after the admission (3 total days).
- Documentation of patient engagement (e.g., office visits, visits to the home, telehealth) provided within 30 days after discharge.
- Documentation of medication reconciliation on the date of discharge through 30 days after discharge (31 total days).

Q: What type of document is acceptable?

A: All of the following documentation in 2021:

- Notification of Inpatient Admission
- Receipt of Discharge Information
- Patient Engagement After Inpatient Discharge
- Medication Reconciliation with medication list
- All progress notes
- Current medication list
- All correspondence (phone call, email, fax) between inpatient provider and member's PCP
- All Hospital/SNF/Rehab discharge summaries

Medication Reconciliation does not require the member to be present

Transitions of Care (TRC)

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Services provided during a telephone visit, e-visit or virtual check-in within 30 days after discharge meet criteria.
- ☑ Ensure presence of all components in the medical record documentation

Transitions of Care (TRC)

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes

CPT codes	
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456
Telephone Visits	98966, 98967, 98968, 99441, 99442, 99443
Transitional Care Management Services	99495, 99496
Medication Reconciliation	99483, 99495, 99496

CPT Telephonic and Telehealth codes	
99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205	

CPT Modifier codes for telehealth	
95, GT, 02	

CPTII	
Medication Reconciliation	1111F

Modifier	
Telehealth	95, GT

Appropriate Treatment for Children with Upper Respiratory Infection (URI)

NCQA Accreditation – Medicaid

Q: Which members are included in the sample?

A: Children 3 months -18 years of age who were given a diagnosis of upper respiratory infection (URI) and were not dispensed an antibiotic prescription in **2020** or **2021**.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What type of document is acceptable?

A: Evidence from claim/encounter data with a date of service for any outpatient or ED visit with **only** a URI diagnosis and no new or refill prescription for an antibiotic on or three days after the Index Episode Start Date (IESD).
Index Episode Start Date (IESD): The earliest date of service for an eligible visit (outpatient, observation, or ED) during Intake Period (July 1, 2020 - June 30, 2021).

Q: How to improve score for this HEDIS® measure?

- A:**
- ☑ Use of complete and accurate Value Set Codes
 - ☑ Timely submission of claim/encounter data
 - ☑ Ensure presence of all components in the medical record documentation
 - ☑ Exclude claim/encounter data with more than one diagnosis code and ED visits or observation visits that result in an inpatient stay

Appropriate Treatment for Upper Respiratory Infection (URI)

NCQA Accreditation – Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes	
URI	J00, J06.0, J06.9
CPT codes	
ED	99281-99285
Observation	99217-99220
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483
Telephone Visit	98966 -98968, 99441- 99443
Online Assessment	98969, 99444
CPT Telephonic and Telehealth codes	
99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205	
CPT Modifier codes for telehealth	
95, GT, 02	
HCPCS codes	
Outpatient	G0402, G0438, G0439, G0463, T1015
Exclusion(s)	
Competing Diagnosis, Inpatient Stay, Pharyngitis 1. HIV Value Set. 2. HIV Type 2 Value Set. 3. Malignant Neoplasms Value Set. 4. Other Malignant Neoplasm of Skin Value Set. 5. Emphysema Value Set.	6. COPD Value Set. 7. Comorbid Conditions Value Set. 8. Disorders of the Immune System Value Set. 9. Pharyngitis Value Set. 10. Competing Diagnosis Value Set.

Well-Child Visits in the First 30 Months of Life (W30)

State Medicaid MPL (must achieve 50th percentile or greater)
Pay-for-Performance (P4P)
NCQA Accreditation - Medicaid

Q: Which members are included in the sample?

A: Children who had the following number of well-child visits with a PCP during the last 15 months.

1. Well-Child Visits in the First 15 Months. Children who turned 15 months old during the measurement year: Six or more well-child visits.
2. Well-Child Visits for Age 15 Months–30 Months. Children who turned 30 months old during the measurement year: Two or more well-child visits between 15 and 30 months of age.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: None. This measure requires **claim/encounter data** submission only using the appropriate Value Set Codes.

Q: What type of medical record is acceptable?

A:

1. Evidence from a claim/encounter with a date of service for any six or more well-child visits on different dates of service on or before the 15-month birthday.
2. Evidence from a claim/encounter with a date of service for any two or more well-child visits on different dates of service between the child's 15-month birthday plus 1 day and the 30-month birthday.

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Use of complete and accurate Value Set Codes.
- ☒ Timely submission of claims and encounter data
- ☒ Use every visit (including sick visit) to provide a well-child visit and immunizations

Well-Child Visits in the First 30 Months of Life (W30)

State Medicaid MPL (must achieve 50th percentile or greater)
Pay-for-Performance (P4P)
NCQA Accreditation - Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

Z00.00, Z00.01, Z00.110, Z00.111, Z00.121, Z00.129, Z00.2, Z00.3, Z02.5, Z76.1, Z76.2

CPT codes

99381-99385, 99391-99395, 99461

HCPCS codes

G0438, G0439, S0302

Exclusion(s)

Hospice setting or Hospice care.

Weight Assessment and Counseling for Nutrition & Physical Activity for Children/Adolescents (WCC)

State Medicaid MPL (must achieve 50th percentile or greater)
NCQA Accreditation – Medicaid

Q: Which members are included in the sample?

A: Members 3-17 years of age who had an outpatient visit with a PCP or OB/GYN and had evidence of BMI percentile with height and weight documentation, counseling for nutrition, and counseling for physical activity in **2021**.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: Documentation in the medical record must include a note indicating the **date** of the office visit and evidence of the following:

- ☒ BMI percentile **or** BMI percentile plotted on age-growth chart
- ☒ Height and weight
- ☒ Counseling for nutrition or referral for nutrition education
- ☒ Counseling for physical activity or referral for physical activity

Q: What type of medical record is acceptable?

A: One or more of the following:

- | | |
|--|---|
| <input checked="" type="checkbox"/> Progress notes/Office visits notes | <input checked="" type="checkbox"/> Complete Physical Examination Form |
| <input checked="" type="checkbox"/> Anticipatory Guidance Form | <input checked="" type="checkbox"/> Dated growth chart/log |
| <input checked="" type="checkbox"/> Staying Healthy Assessment Form | <input checked="" type="checkbox"/> Nutrition and Physical Activity Assessment Form |
| <input checked="" type="checkbox"/> Member-collected biometric values (height, weight, BMI percentile) meet criteria for the BMI Percentile numerator. | <input checked="" type="checkbox"/> What Does Your Child Eat Form |

Weight Assessment and Counseling for Nutrition & Physical Activity for Children/Adolescents (WCC)

State Medicaid MPL (must achieve 50th percentile or greater)

NCQA Accreditation – Medicaid

Q: How to improve score for this HEDIS® measure?

A:

- ☑ Use of complete and accurate Value Set Codes
- ☑ Timely submission of claim/encounter data
- ☑ Services rendered during a telephonic visit, e-visit or virtual check-in meet criteria for the Counseling for Nutrition and Counseling for Physical Activity indicators.
- ☑ Ensure presence of all components in the medical record documentation

Exclusion (optional): A diagnosis of pregnancy in 2021 for female members only.

Note: Services specific to the assessment or treatment of an acute or chronic condition do not count toward the “Counseling for nutrition” and “Counseling for physical activity” indicators.

Weight Assessment and Counseling for Nutrition & Physical Activity for Children/Adolescents (WCC)

State Medicaid MPL (must achieve 50th percentile or greater)

NCQA Accreditation – Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes	
BMI Percentile	Z68.51-Z68.54
Nutrition Counseling	Z71.3
Physical Activity Counseling	Z02.5, Z71.82
CPT codes	
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99455, 99456, 99483
Nutrition Counseling	97802-97804
CPT Telephonic and Telehealth codes	
99441-99443, 98966-98968, 99444, 99212-99215, 99201-99205	
T Modifier codes for telehealth	
95, GT, 02	
HCPCS codes	
Outpatient	G0402, G0438, G0439, G0463, T1015
Nutrition Counseling	G0270, G0271, G0447, S9449, S9452, S9470
Physical Activity Counseling	G0447, S9451
Exclusion(s)	
Pregnancy	

Child and Adolescent Well-Care Visits (WCV)

State Medicaid MPL (must achieve 50th percentile or greater)
Pay-for-Performance (P4P)
NCQA Accreditation - Medicaid

Q: Which members are included in the sample?

A: Members 3-21 years of age who had at least one (1) comprehensive well-care visit with a PCP or an OB/GYN practitioner in 2021.

Q: What codes are used?

A: Please reference attached sample codes and Value Set Directory for additional codes.

Q: What documentation is needed in the medical record?

A: *None.* This measure requires claim/encounter data submission only using the appropriate Value Set Codes.

Q: How to improve score for this HEDIS® measure?

A:

- ☒ Use of complete and accurate Value Set Codes
- ☒ Timely submission of claim/encounter data
- ☒ Submission of telehealth claim/encounter

Child and Adolescent Well-Care Visits (WCV)

State Medicaid MPL (must achieve 50th percentile or greater)
Pay-for-Performance (P4P)
NCQA Accreditation - Medicaid

SAMPLE CODES

The codes listed below are not inclusive and do not represent a complete list of codes.

ICD-10 codes

Z00.00, Z00.01, Z00.110, Z00.111, Z00.121, Z00.129, Z00.2, Z00.3, Z02.5, Z76.1, Z76.2

CPT codes

99381-99384, 99391-99395

HCPCS codes

G0438, G0439, S0302

Exclusion(s)

Hospice setting or Hospice care.